CURRICULUM VITAE
GENERAL INFORMATION
JOEL LEXCHIN
Office:
Room 420
Health Nursing and Environmental Studies Building
Faculty of Health
Tel: 416-736-2100 x 22119
Fax: 416-736-5227
E mail: jlexchin@yorku.ca
Home:
121 Walmer Rd.
Toronto ON
M5R 2X8
Tel: 416-964-7186
Education
1977-1979
1973-1977
1971-1973
1966-1971
Family Practice Residency, Dalhousie University
M.D., University of Toronto
M.Sc., Institute of Medical Sciences, University of Toronto
Specialization: Neurochemistry
Thesis: 5-hydroxytryptamine and the blood brain barrier in rats
Four year B.Sc. in life sciences, University of Toronto
Current Positions
20061988-
Professor, School of Health Policy and Management, Faculty of
Health
Emergency Physician, Department of Emergency Medicine,
University Health Network
Previous Positions
2001-2006
2000
2000
19961996-98
Associate Professor, School of Health Policy and Management,
Atkinson Faculty of Liberal and Professional Studies
Emergency Physician, Department of Emergency Medicine, Lyell
McEwin Health Service, South Australia
Researcher, Australian Medicines Handbook
Associate Professor, Department of Family and Community
Medicine University of Toronto
Editor, Drugs of Choice
1991-96
1988-91
1982-88
1982-1988
Assistant Professor, Department of Family and Community
Medicine, University of Toronto
Lecturer, Department of Family and Community Medicine
University of Toronto
Lecturer in the.
Assistant Clinical Professor, Department of Family Medicine,
McMaster University
Emergency Physician, Hamilton Civic Hospitals
Honours and Awards
2012
20092008
2005
2004
2004
2003
2001
2000199719961992
1984
1983
Fellow, Canadian Academy of Health Sciences
Affiliate, Centre for Health Services and Policy Research,
University of British Columbia
Winner Dean’s award for research (established career), Faculty of
Health, York University
Award for research excellence 2004. Department of Family and
Community Medicine, University of Toronto
Annual Willis Cunningham memorial lecture in law and medicine,
Faculty of Law, Queen’s University, Kingston
SWAB (Stichting Werkgroep Antibioticabeleid) Award
Atkinson junior faculty research award
Atkinson travel grant to present paper at American Public Health
Association annual meeting
Research Associate, Canadian Centre for Policy Alternatives
Associate Member, Centre for Evaluation of Medicines,
McMaster University
Fellow of the Canadian College of Family Physicians
Diplomate, American Board of Emergency Medicine
Certificant College of Family Physicians—Emergency
Medicine
Certificant College of Family Physicians
PROFESSIONAL CONTRIBUTION AND STANDING
PUBLICATIONS
Books
Lexchin J. Drug therapy for emergency physicians. Ottawa: Canadian Association of
Emergency Physicians, 2002.
Levine M, Lexchin J, Pellizzari R. Drugs of choice: a formulary for general practice, 3rd
ed. Ottawa: Canadian Medical Association, 1998.
Levine M, Lexchin J, Pellizzari R. Drugs of choice: a formulary for general practice, 2nd
ed. Ottawa: Canadian Medical Association, 1997.
Levine M, Lexchin J, Pellizzari R. Drugs of choice: a formulary for general practice.
2
Ottawa: Canadian Medical Association, 1995.
Lexchin J. Deception by design: pharmaceutical promotion in the third world. Penang:
Consumers International, 1995.
Lexchin J. The real pushers: a critical analysis of the Canadian drug industry.
Vancouver: New Star Press, 1984.
Chapters in Books – Peer Reviewed
Lexchin J. Social responsibility and marketing of drugs in developing countries: a goal or
an oxymoron. In: Forman J, Kohler JC eds. Access to medicines as a human right:
implications for pharmaceutical industry responsibility. Toronto: University of
Toronto Press, 2012:125-147.
Lexchin J. The pharmaceutical industry and Health Canada: values in conflict. In:
Germov J, Hornosty J eds. Second opinion: an introduction to health sociology,
first Canadian edition. Toronto: Oxford University Press, 2011:277-295.
Lexchin J. Medicines and money: the corruption of clinical information. In: Burke RJ,
Tomlinson EC, Cooper CL eds. Crime and corruption in organizations: why it
occurs and what to do about it. Surrey: Gower, 2010:249-271.
Lexchin J. Pharmaceutical policy: the dance between industry, government, and the
medical profession. In: Raphael D, Bryant T, Rioux M eds. Staying alive: critical
perspectives on health, illness, and health care 2nd ed. Toronto: Canadian
Scholars’ Press Inc., 2010:371-393.
Ziganshina L, Lexchin J. Regulation of pharmaceutical promotion: why does regulation
matter? In: Mintzes B, Mangin D, Hayes L eds. Understanding and responding to
pharmaceutical promotion: a practical guide. World Health Organization/Health
Action International, 2009:123-144.
Lexchin J. Analysing pharmaceutical advertisements in medical journals. In: Mintzes B,
Mangin D, Hayes L eds. Understanding and responding to pharmaceutical
promotion: a practical guide. World Health Organization/Health Action
International, 2009:41-60.
Lexchin J. Continuing education. In: Rowe BH, Lang ES, Brown MD, Houry D,
Newman DH, Wyer PC eds. Evidence-based emergency medicine. Chichester:
Wiley-Blackwell, 2009:34-42.
Lexchin J, Wiktorowicz M. Profits first: the pharmaceutical industry in Canada. In:
Bolaria BS, Dickinson H eds. Health, illness, and health care in Canada. 4th ed.
Toronto: Nelson, 2008:437-457.
Vitry A, Lexchin J, Mansfield P. Is Australia’s national medicines policy failing: the case
of COX-2 inhibitors. In: O’Donovan O, Glavanis-Grantham K eds. Power,
politics and pharmaceuticals. Cork: Cork University Press, 2008:183-192.
Lexchin J. New directions in Canadian drug regulation: whose interests are being served?
In: O’Donovan O, Glavanis-Grantham K eds. Power, politics and
pharmaceuticals. Cork: Cork University Press, 2008:153-170.
Cassels A, Lexchin J. Potential savings from therapeutic substitution of 10 of Canada’s
most dispensed prescription drugs. In: Temple NJ, Thompson A eds. Excessive
medical spending: facing the challenge. Oxford: Radcliffe Publishing, 2007:8092.
3
Balay-Karperien A, Temple NJ, Lexchin J. The marketing of drugs: how drug companies
manipulate the prescribing habits of doctors. In: Temple NJ, Thompson A eds.
Excessive medical spending: facing the challenge. Oxford: Radcliffe Publishing,
2007:53-62.
Lexchin J. Drug regulation: two paradigms in conflict. In: Temple NJ, Thompson A eds.
Excessive medical spending: facing the challenge. Oxford: Radcliffe Publishing,
2007:36-52.
Lexchin J. The pharmaceutical industry and the pursuit of profit. In: Cohen JC,
Illingworth P, Schüklenk U eds. The power of pills: social, ethical & legal issues
in drug development, marketing & pricing. London: Pluto Press, 2006:11-24.
Lexchin J. Pharmaceutical policy: the dance between industry, government, and the
medical profession. In: Raphael D, Bryant T, Rioux M eds. Staying alive: critical
perspectives on health, illness, and health care. Toronto: Canadian Scholars’ Press
Inc., 2006:325-345.
Lexchin J. Profits first: the pharmaceutical industry in Canada. In: Bolaria BS,
Dickinson H eds. Health, illness, and health care in Canada. 3rd ed. Toronto:
Nelson, 2001:389-408.
Lexchin J. Pharmaceuticals: politics and policy. In: Armstrong P, Armstong H, Coburn D
eds. Unhealthy times: political economy perspectives on health and care in
Canada. Toronto: Oxford University Press, 2001:31-44.
Lexchin J. Controlling pharmaceutical expenditures in Canada. In: Drache D, Sullivan
T eds. Health reform: public success, private failure. London: Routledge,
1999:292-311.
Lexchin J. Profits first: the pharmaceutical industry. In: Bolaria BS, Dickinson
H eds. Health, illness, and health care in Canada. 2nd ed. Toronto: Harcourt
Brace Jovanovich, 1994:700-720.
Lexchin J. Profits first: the pharmaceutical industry. In: Bolaria BS, Dickinson
H eds. Sociology of health and health care in Canada. Toronto: Harcourt Brace
Jovanovich, 1988:497-513.
Chapters in Books – Not Peer Reviewed
Lexchin J. Pharmacare: equity, efficiency, and effectiveness – we’ve waited long enough.
In: Campbell B, Marchildon G eds. Medicare: facts, myths, problems and
promise. Toronto: Lorimer, 2007:262-7.
Lexchin J. Drug makers and drug regulators: too close for comfort. A study of the
Canadian situation. In: Coburn D, D’Arcy C, Torrance GM eds. Health and
Canadian society: sociological perspectives. Toronto: University of Toronto
Press, 1998:485-96.
Lexchin J. Pharmaceutical industry. The Canadian Encyclopedia 1998 CD-ROM
Toronto: McClelland and Stewart, 1998.
Lexchin J. O controle da promocao farmaceutica [Control over pharmaceutical
promotion]. In: Ruben de Alcantara Bonfim J, Mercucci VL eds. A construcao
da politica de medicamentos. Sao Paulo: SOBRAVIME, 1997:293-304.
Lexchin J. Uma fraude planejada: a publicidade farmaceutica no terceiro mundo
4
[Deception by design: pharmaceutical promotion in the Third World]. In:
Ruben de Alcantara Bonfim J, Mercucci VL eds. A construcao da politica de
medicamentos. Sao Paulo: SOBRAVIME, 1997:269-289
Lexchin J, Kawachi I. Voluntary codes of pharmaceutical marketing: controlling
promotion or licensing deception. In: Davis P ed. Contested ground: public
purpose and private interest in the regulation of prescription drugs. New York:
Oxford University Press, 1996:221-235.
Lexchin J. Public good [health] or private profits: focus on pharmaceutical issues.
In: Bolaria BS, Bolaria R eds. Women, medicine and health. Halifax: Fernwood
Publishing, 1994:39-55.
Lexchin J. Introduction. In: Armstrong P, Armstrong H, Choiniere J, Feldberg
G, White J. Take care: warning signals for Canada’s health system. Toronto:
Garamond Press, 1994:9-13.
Kawachi I, Lexchin J. Doctors and the drug industry: therapeutic information or
pharmaceutical promotion. In: Davis P ed. For health or profit? Medicine, the
pharmaceutical industry and the state in New Zealand. Auckland: Oxford
University Press, 1992:245-68.
Lexchin J, Norris P. Patents and generics: a campaign diary. In: Davis P ed.
For health or profit? Medicine, the pharmaceutical industry and the state in New
Zealand. Auckland: Oxford University Press, 1992:229-44.
Lexchin J. Pharmaceutical industry. In: Marsh JH, ed. The Canadian
Encyclopedia, 2nd ed. Edmonton: Hurtig Publishers Ltd., 1988:1655-6.
Lexchin J. Determinants of physician prescribing patterns and behavior. In:
Goldberg T, DeVito CA, Raskin IE eds. Generic drug laws: a decade of trial--a
prescription for progress. Washington: U.S. Department of Health and Human
Services, June 1986:71-98.
Books – other
Rochon Ford A, Saibil D eds. The push to prescribe: women & Canadian drug policy.
Toronto: Women’s Press, 2009. (Member of editorial committee that oversaw
development and writing of the book)
Pamphlets
Gindin S, Armstrong H, Armstrong P, Leys C, Lister J, Lexchin J, Hurley M, Mehra N.
Whose health care? Challenging the corporate struggle to rule our system.
Socialist Interventions Pamphlet Series, 2005.
Articles (Refereed)
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and
research outcome (review). Cochrane Database of Systematic Reviews 2012,
Issue 12. Art. No.: MR000033. DOI: 10.1002/14651858.MR000033.pub2.
Lexchin J. New drugs and safety: what happened to new active substances approved in
5
Canada between 1995 and 2010? Archives of Internal Medicine 2012:172:16801.
Lexchin J. Sponsorship bias in clinical research. International Journal of Risk & Safety in
Medicine 2012;24:233-242.
Roseman M, Turner EH, Lexchin J, Coyne JC, Bero L, Thombs BD. Reporting of
conflicts of interest from drug trials in Cochrane reviews: cross sectional study.
BMJ 2012;345:e5155.
Light D, Lexchin J. Pharmaceutical research and development: what do we get for all
that money? BMJ 2012;344:e4348.
Lexchin, J. Models for financing the regulation of pharmaceutical promotion.
Globalization and Health 2012;8:24.
Lexchin J. Those who have the gold make the evidence: how the pharmaceutical industry
biases the results of clinical trials of medications. Science and Engineering Ethics
2012;18:247-261.
Wiktorowicz M, Lexchin J, Moscou K. Pharmacovigilance in Europe and North
America: divergent approaches. Social Science & Medicine 2102;75:165-170.
Lexchin J. Of money and trust in medical care redux. Mens Sana Monographs
2012;10:143-149
Lexchin J. International comparison of assessments of drug innovation. Health Policy
2012;105:221-225.
Lexchin J. Harmony in drug regulation, but who’s calling the tune? An examination of
regulatory harmonization in Health Canada. International Journal of Health
Services 2012;42:119-136.
Lexchin J, Kohler JC. The danger of imperfect regulation: OxyContin use in the United
States and Canada. International Journal of Risk & Safey in Medicine
2011;23:233-40.
Bouchard RA, Cahoy D, Domeij B, Dutfield G, Faunce T, Hollis A, Jones P, Ali Khader
F, Lexchin J, Nam H, Serrano JL. Global pharmaceutical linkage regulations: a
consortium framework. Minnesota Journal of Law, Science & Technology
2011;12(2):391-461.
Lexchin J. Coverage with evidence development for pharmaceuticals: a policy in
evolution? International Journal of Health Services 2011;41:337-54.
Holbrook A, Lexchin L, Willison D, Pullenayegum E, Troyan S, Campbell C, Marlow B,
Weijer C, Blackmer J, Brazil K. Public Opinions on Physician-Pharmaceutical
Industry Interactions: A Canadian Survey. J Popul Ther Clin Pharmacol
2011;18(2):e185.
Lexchin J. Canada's patented medicine notice of compliance regulations: balancing the
scales or tipping them? BMC Health Services Research 2011;11:64.
Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug
development: a systematic review. Health Policy 2011;100:4-17.
Rosenbaum M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD.
Reporting of conflicts of interest in meta-analyses of trials of pharmacological
treatments. JAMA 2011;305:1008-17.
Becker A, Dörter F, Eckhardt K, Viniol A, Baum E, Kochen MM, Lexchin J,
Wegscheider K, Donner-Banzhoff N. The association between a journal’s source
6
of revenue and the drug recommendations made in articles it publishes. CMAJ
2011;183:544-8.
Rochon PA, Sekeres M, Hoey J, Lexchin J, Ferris LE, Moher D, Kalkar SR, Van
Laethem M, Gruneir A, Gold J, Maskalyk J, Streiner DL, Taback N, Chan A-W.
Investigator experiences with financial conflicts of interest in clinical trials. Trials
2011;12:9.
Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI.
Information from pharmaceutical companies and the quality, quantity, and cost of
physicians’ prescribing: a systematic review. PLoS Medicine 2010;7:e1000352.
Lexchin J. One step forwards, one step sideways? Expanding research capacity for
neglected diseases. BMC International Health and Human Rights 2010;10:20.
Lexchin J. Marketing before patenting: implications for price controls in Canada. Open
Medicine 2010;4:E139-E142.
Rochon PA, Sekeres M, Lexchin J, Moher D, Wu W, Kalkar SR, van Laethem M, Hoey
J, Chan A-W, Gruneir A, Gold J, Maskalyk J, Streiner DL, Taback N, Ferris LE.
Institutional financial conflicts of interest policies at Canadian academic health
science centres: a national survey. Open Medicine 2010;4:e134-138.
Lexchin J. Statistics in drug advertising: what they reveal is suggestive what they hide is
vital. International Journal of Clinical Practice 2010;64:1015-1018.
Lexchin J, Arya N, Singh S. Gardasil® - the new HPV vaccine: the right product, the
right time? A commentary. Healthcare Policy 2010;5:26-36
Lexchin J. Drug safety and Health Canada. International Journal of Risk and Safety in
Medicine 2010;22:41-53.
Rochon P, Hoey J, Chan A-W, Ferris LE, Lexchin J, Kalkar SR, Sekeres M, Wu W, Van
Laethem M, Gruneir A, Maskalyk J, Streiner DL, Gold J, Taback N, Moher D.
Financial conflicts of interest checklist 2010 for clinical research studies. Open
Medicine 2010;4:E69-E91.
Lexchin J. Pharmaceutical innovation: can we live forever? A commentary on Schnittker
and Karandinos. Social Science & Medicine 2010;70:972-3.
Kohler Jillian Clare, Lexchin Joel, Kuek Victoria, Orbinski James. Canada’s access to
medicines regime: promise or failure of humanitarian effort? Healthcare Policy
2010;5:40-8.
Lexchin J, O’Donovan O. Prohibiting or ‘managing’ conflict of interest? A review of
policies and procedures in three European drug regulation agencies. Social
Science & Medicine 2010;70:643-647
Tannenbaum C, Lexchin J, Tamblyn R, Romans S. Indicators for measuring mental
health: towards better surveillance. Healthcare Policy 2009;5:e177-e186.
Lexchin J. CJEM and pharmaceutical advertisements: it’s time for an end. CJEM
2009;11:375-9.
Lexchin J. Pricing of multiple dosage prescription medications: an analysis of the Ontario
Drug Benefit Formulary. Health Policy 2009;91:142-7.
Lexchin J, Mintzes B. Medicine reimbursement recommendations in Canada, Australia,
and Scotland. American Journal of Managed Care 2008;14:581-8.
Lexchin J. Clinical trials in Canada: whose interests are paramount? International Journal
of Health Services 2008;38:525-42.
Lexchin J, Sekeres M, Gold J, Ferris LE, Kalkar SR, Wu W, Van Laethem M, Moher D,
7
Maskalyk MJ, Taback N, Rochon PA. National evaluation of policies on
individual financial conflicts of interest in Canadian academic health science
centers. Journal of General Internal Medicine 2008;23:1896-1903.
Lexchin J. Doctors and industry funding of continuing medical education: guilty as
charged. Israeli Journal of Emergency Medicine 2008;8:23-25.
Mykhalovskiy E, Armstrong P, Armstrong H, Bourgeault I, Choiniere J, Lexchin J,
Peters S, White J. Qualitative research and the politics of knowledge in an age of
evidence: developing a research-based practice of immanent critique. Social
Science & Medicine 2008;67:195-203.
Cassels A, Lexchin J. How well do Canadian media outlets convey medical treatment
information. Open Medicine 2008;2(2):e20-23.
Allan GM, Lexchin J. Physician awareness of diagnostic and nondrug therapeutic costs: a
systematic review. International Journal of Technology Assessment in Health
Care 2008;24:158-165.
Vitry A, Lexchin J, Sasich L, Dupin-Spriet T, Reed T, Bertele V, Garattini S, Toop L,
Hurley E. Provision of information on regulatory authorities’ websites. Internal
Medicine Journal 2008;38:559-567.
Lexchin J. Drug approval times and user fees: an international perspective in a changing
world. Pharmaceutical Medicine 2008;22:1-11.
Sekeres M, Gold, JL, Chan A-W, Lexchin J, Moher D, Van Laethem MLP, Maskalyk J,
Ferris L, Taback N, Rochon PA. Poor reporting of scientific leadership
information in clinical trial registers. PLoS One 2008;3:e1610.
Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical
promotion expenditures in the United States. PLoS Medicine 2008;5:e1.
Lexchin J. The secret things belong unto the lord our god: secrecy in the pharmaceutical
arena. Medicine and Law 2007;26:417-30.
Vitry A, Lexchin J, Mansfield PR. Is Australia’s national medicines policy failing? The
case of COX-2 inhibitors. International Journal of Health Services 2007;37:73544.
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review.
PLOS Med 2007;4(9): e283.
Faunce TA, Lexchin J. Linkage pharmaceutical evergreening in Canada and Australia.
Australia and New Zealand Health Policy 2007;4:8. (Available on-line at
http://www.anzhealthpolicy.com/content/pdf/1743-8462-4-8.pdf)
Lexchin J. Notice of compliance with conditions: a policy in limbo. Healthcare Policy
2007;2(4):114-122.
Lexchin J. Of money and trust in medical care. Mens Sana Monographs 2007;5(1):7-10.
Guyatt G, Devereaux PJ, Lexchin J, Stone SB, Yalnizyan A, Himmelstein D,
Woolhandler S, Zhou Q, Goldsmith LJ, Cook DJ, Haines T, Lacchetti C, Lavis
JN, Sullivan T, Mills E, Kraus S, Bhatnagar N. A systematic review of studies
comparing health outcomes in Canada and the United States. Open Medicine
2007;1:E27-36.
Lexchin J. Relationship between pharmaceutical company user fees and drug approvals
in Canada and Australia: a hypothesis-generating study. Annals of
Pharmacotherapy 2006;40:2216-22.
Mansfield P, Lexchin J, Wen LS, Grandori L, McCoy C, Hoffman JR, Ramos J, Jureidini
8
JN. Educating health professionals about drug and device promotion: advocates’
recommendations. PLoS Medicine 2006;3:e451.
Lexchin J. A comparison of new drug availability in Canada and the United States and
potential therapeutic implications of differences. Health Policy 2006;79:214-20.
Lexchin J, Light D. Commercial influence and the content of medical journals. BMJ
2006;332:1444-7.
Lexchin J. Withdrawals of drugs for safety reasons: how do regulators decide if they are
too unsafe. Adverse Drug Reaction Bulletin Feb. 2006: No. 236:903-6.
Lexchin J. Do manufacturers of brand-name drugs engage in price competition? An
analysis of introductory prices. CMAJ 2006;174:1120-1.
Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction. PLoS Medicine
2006;3(4):e132.
Roughead EE, Lexchin J. Adverse drug events: counting is not enough, action is needed.
MJA 2006;184:315-6.
Lexchin J. Who should own the presses? Israeli Journal of Emergency Medicine
2006;6(2):4-6.
Lexchin J. Price controls for prescription drugs: Canada does it, so can the United States.
Connecticut Journal of International Law 2005;20:243-55.
Light DW, Lexchin J. Foreign free riders and the high price of US medicines. BMJ
2005;331:958-60.
Lexchin J. Commentary: nesiritide and lessons unlearned. Israeli Journal of Emergency
Medicine 2005;5:69-72.
Mintzes B, Barer M, Lexchin J, Bassett K. Introduction of direct-to-consumer advertising
of prescription drugs in Canada: an opinion survey on regulatory policy. Research
in Social and Administrative Pharmacy 2005;1:310-330.
Lexchin J. Intellectual property rights and the Canadian pharmaceutical marketplace:
where do we go from here? International Journal of Health Services 2005;35:237
56.
Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
CMAJ 2005;172:765-7.
Mintzes B, Lexchin J. Do higher drug costs lead to better health? Canadian Journal of
Clinical Pharmacology 2005;12:e22-e27.
Lexchin J. Implications of pharmaceutical industry funding on clinical research.
Annals of Pharmacotherapy 2005;39:194-197.
Lexchin J. The effect of generic competition on the price of brand-name drugs. Health
Policy 2004;68:47-54. (5th most downloaded article from Health Policy January –
June 2004)
Lexchin J., Grootendorst P. The effects of prescription drug user fees on drug and
health services use and health status: a review of the evidence. International
Journal of Health Services 2004;34:101-122.
Lexchin J. Are new drugs as good as they claim to be? Australian Prescriber 2004;27:23.
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R,
Marion SA. Is there a dose-response relationship between direct-to-consumer
9
advertising and patient requests for medicines in primary care? Cross-sectional
survey of two levels of advertising exposure. CMAJ 2003;169:405-12.
Lexchin J. Op-Ed: safeguarding the quality of clinical research. Virtual Mentor
2003;5(7). Available at http://www.ama-assn.org/ama/pub/printcat/10619.html
Lexchin J, Bero L, Djubegovic B, Clark O. Pharmaceutical industry sponsored
research: evidence for a systematic bias. BMJ 2003;326:1167-70.
Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack J. Drugs in the
news. An analysis of Canadian newspapers coverage of new prescription drugs.
CMAJ 2003;168:1133-7.
Lexchin J. Should doctors prescribe new drugs? International Journal of Risk and
Safety in Medicine 2002;15:213-22.
Henry D, Lexchin J. Industry as a medicines provider. Lancet 2002;360:1590-6.
Lexchin J, Mintzes B. Direct-to-consumer advertising of prescription drugs: the
evidence says no. Journal of Public Policy and Management 2002;21(2):194-201.
Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, Dubois S, Russo R. Assessing the
quality of drug detailing. Journal of Clinical Epidemiology 2002;55:825-32.
Lexchin J. New drugs with novel therapeutic characteristics: have they been subject to
randomized controlled trials? Can Fam Physician 2002;48:1487-92.
Hugenholtz H, Cass DE, Dvorak MF, Fewer DH, Fox RJ, Izukawa DMS, Lexchin
J, Tuli S, Bharatwal N, Short C. High-dose methylprednisolone for acute closed
spinal cord injury--only a treatment option. Can J Neurolog Sci 2002;29:227235.
Lexchin J. Call for a national pharmacare plan. Canadian Review of Social Policy
2002;No. 48:114-9
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG,
Pan R, Marion SA. Influence of direct to consumer pharmaceutical advertising
and patients' requests on prescribing decisions: two site cross sectional survey.
BMJ 2002;324:278-9.
Lexchin J. Effects of restrictive formularies in the ambulatory care setting.
American Journal of Managed Care 2002;8:69-76.
Lexchin J. Lifestyle drugs: issues for debate. CMAJ 2001;164:1449-51.
Vlassov V, Mansfield P, Lexchin J, Vlassova A. Do drug advertisements in
Russian medical journals provide essential information for safe prescribing.
West J Med 2001;174:391-4.
Bourgeault IL, Armstrong P, Armstrong H, Choiniere J, Lexchin J, Mykhalovskiy E,
Peters S, White J. Everyday experiences of implicit rationing: comparing the
voices of nurses in California and British Columbia. Sociology of Health &
Illness 2001;23:633-653.
Lexchin J. Double standards: double jeopardy. Pharmacoepidemiology and Drug Safety
2000;9:289-90.
Lexchin J. Click, click: the internet and prescription drugs. Australian Prescriber
2000;23:73-4.
Lexchin J. Direct-to-consumer advertising: impact on patient expectations
regarding disease management. Dis Manage Health Outcomes 1999;5:273-83.
Lexchin J. How patient outcomes are reported in drug advertisements: review of
Canadian medical journals. Can Fam Physician 1999;45:1213-6.
10
Lexchin J. Hear no secrets, see no secrets, speak no secrets: secrecy in the
Canadian drug approval system. Int J Hlth Serv 1999;29:167-78.
Lexchin J. The relationship between pharmaceutical regulation and inappropriate
prescribing: the case of psychotropic drugs in Canada during the 1960s and early
1970s. Int J Risk Safety Med 1998;11:49-59. (Translation of: Réglementation
pharmaceutique au Canada et prescription inadéquate de médicaments: le cas des
psychotropes dans les années 60 et au début des anneés 70. Santé mentale au
Québec 1996;22:283-300.)
Lexchin J. Secrecy and the Health Protection Branch. CMAJ 1998;159:481-3.
Lexchin J. Improving the appropriateness of physician prescribing. Int J Hlth
Serv 1998;28:253-67.
Lexchin J. Code of marketing practices: voluntary self-regulation for the
Pharmaceutical Manufacturers Association of Canada. Can Fam Physician
1997;43:1997.
Lexchin J. What information do physicians receive from pharmaceutical
representatives? Can Fam Physician 1997;43:941-5.
Lexchin J. After compulsory licensing: coming issues in Canadian pharmaceutical
policy and politics. Health Policy 1997;40:69-80.
Lexchin J. Enforcement of codes governing pharmaceutical promotion: what
happens when companies breach advertising guidelines? Can Med Assoc J
1997;156:351-357.
Lexchin J. Réglementation pharmaceutique au Canada et prescription inadéquate de
médicaments: le cas des psychotropes dans les années 60 et au début des anneés
70. Santé mentale au Québec 1996;22:283-300.
Shear NH, Black F, Lexchin J. Examining the physician-detailer interaction. Can
J Clin Pharmacol 1996;3:175-179.
Anderson GM, Lexchin J. Strategies for improving prescribing practice. Can Med
Assoc J 1996;154:1013-1017.
Lexchin J. Income class and pharmaceutical expenditure in Canada: 1964-1990.
Can J Pub Health 1996;87:46-50.
Lexchin J. Cost effective pharmaceutical care for the elderly and the formulation of
pharmaceutical policy in Canada. Health and Canadian Society 1995;3:119-133.
Lexchin J. Is there a bias in industry supported clinical research? Can J Clin
Pharmacol 1995;2:15-8.
Lexchin J. The timeliness of new drug approvals in Canada: a rejoinder. Int J Hlth Serv
1995;25:167-71.
Lexchin J. Agents against pediatric diarrhea: assessing the information companies
supply to Canadian physicians. Can Fam Physician 1994;40:2082-7.
Lexchin J, Holbrook, A. An assessment of the methodologic quality and relevance of
references in pharmaceutical advertisements in a Canadian medical journal. Can
Med Assoc J 1994;151:47-54.
Lexchin J. Who needs faster drug approval times in Canada: the public or the
industry? International Journal of Health Services 1994;24:253-264.
Lexchin J. Canadian marketing codes: how well are they controlling
pharmaceutical promotion. International Journal of Health Services 1994;24:91104.
11
Lexchin J. Interactions between physicians and the pharmaceutical industry: what
does the literature say? Can Med Assoc J 1993;149:1401-7.
Lexchin J. Pharmaceuticals, patents and politics: Canada and Bill C-22.
International Journal of Health Services 1993;23:147-60.
Lexchin J. The effect of generic competition on the price of prescription drugs in the
Province of Ontario. Can Med Assoc J 1993;148:35-8.
Lexchin J. Prescribing and drug costs in the province of Ontario. International
Journal of Health Services 1992;22:471-87.
Lexchin J. Promotion in the third world. Journal of Drug Issues 1992;22:417-53.
Lexchin J. Adverse drug reactions: a review of the Canadian literature. Can Fam
Physician 1991;37:109-18.
Lexchin J. Drug makers and drug regulators: too close for comfort. A study of the
Canadian situation. Soc Sci Med 1990;31:1257-63.
Lexchin J. The portrayal of the elderly in drug advertisements: a factor in
inappropriate prescribing? Can J Aging 1990;9:296-302.
Thomas M, Lexchin J. Pharmaceutical manufacturers' responsiveness to
physicians' requests for information: a comparison of brand and generic
companies. Soc Sci Med 1990;31:153-7.
Lexchin J. Prescribing by Canadian general practitioners: a review of the English
language literature. Can Fam Physician 1990;36:465-70.
Lexchin J. Doctors and detailers: therapeutic education or pharmaceutical
promotion? International Journal of Health Services 1989;19:663-79.
Lexchin J. Prescribing to the elderly: a review of the English language Canadian
literature. Can Fam Physician 1989;35:1613-7.
Lexchin J. The medical profession and the pharmaceutical industry: an unhealthy
alliance. International Journal of Health Services 1988;18:603-16.
Lexchin J. Pharmaceutical promotion in New Zealand. Community Health Studies
1988;12:264-72.
Lexchin J. Pharmaceutical promotion in Canada: convince them or confuse them.
International Journal of Health Services 1987;17:77-89.
Lexchin J, Cude-Simpson KD, Stancer HC. Brain and blood indole metabolites after
peripheral administration of 14C-5-HT in rat. Neurochemical Research
1977;2:39-50.
Articles (Non-Refereed)
Doshi P, Abi-Jaoude E, Lexchin J, Jefferson T, Thomas RE. Innapropriate citation gives
misleading evidence [letter]. CMAJ Posted on-line 7 Nov. 2012:
http://www.cmaj.ca/content/early/2012/10/29/cmaj.121679.citation/reply#cmaj_e
l_713497
Lexchin J, Vitry A. Should the C in CME stand for commercial? Southern Med Review
2012;5:3-5.
Braillon A, Bewley S, Herxheimer A, Mansfield P, Lexchin J, Menkes DB, Ziganshina
LE, Montastruc J-L. Marketing versus evidence-based medicine [letter]. Lancet
2012;380:340.
Lexchin J. Ban drug advertisements. CJEM 2011;13:297.
12
Lexchin J. Rebuttal: does family medicine have a professional obligation to play a
leading role in pharmaceutical industry-sponsored drug research? No. Can Fam
Physician 2011;57:e277.
Lexchin J. Does family medicine have a professional obligation to play a leading role in
pharmaceutical industry-sponsored drug research? No. Can Fam Physician
2011;57:871, 873.
Spurling G, Mansfield P, Lexchin J. Pharmaceutical advertising in The Lancet. [letter]
Lancet 2011;378:30.
Light D, Lexchin J, Schaber J. Longer exclusivity does not guarantee better drugs [letter].
Health Affairs 2011;30:798.
Birn A-E, Lexchin J. The GAVI Alliance, AMCs and improving immunization coverage
through public sector vaccine production in the global south. Human Vaccines
2011;7(3):1-2.
Lexchin J, Spurling G, Mansfield P. Advertising does affect prescribing (e letter).
Canadian Family Physician 2010:56. Posted on-line 7 Nov at
http://www.cfp.ca/cgi/eletters/56/10/e357.
Lexchin J. Industry-supported meta-analyses compared with meta-analyses with nonprofit or no support: differences in methodological quality and conclusions commentary. The Cochrane Collaboration Methods Groups Newsletter
2009;13:9.
Lexchin J. More than the diagnosis (letter). Can Fam Physician 2009;55:689.
Biron P, Mintzes B, Lexchin J, Gagnon M-A, Wright JM, Hofmann A, Musini V. Is the
Diovantage® patient support program direct-to-consumer advertising. Canadian
Journal of Clinical Pharmacology 2009;16:e285-e286. Posted on-line 15 May at
http://www.cjcp.ca/pdf/CJCP08045_e285-e286.pdf
Lexchin J. Coca-Cola is not innocent (e letter). CMAJ 2008. Posted on-line 6 Nov. at
http://www.cmaj.ca/cgi/eletters/179/9/931-b#25130
Lexchin J. Further problems with clinical trial inspections (e letter). CMAJ 2008. Post
on-line 29 Sept. at http://www.cmaj.ca/cgi/eletters/179/7/635#20611
Lexchin J. Progressive licensing of drugs: music or noise? Healthcare Policy
2008;3(4):11-15.
Lexchin J, Bassett K, Biron P, Mansfield P, Mintzes B. Medications for obesity (letter).
Canadian Family Physician 2008;54:848-9.
Lexchin J. Information about a discontinued drug (letter). CMAJ 2008;178:730.
Vitry A, Mintzes B, Lexchin J. Direct-to-consumer advertising policy in Australia:
realism in whose interests (letter). Internal Medicine Journal 2007;37:665-6.
Zito JM, Socolar SJ, Eilers R, Crystal S, Lexchin J. Regulating drugs for effectiveness
and safety: a public health perspective. Medical Care 2007;45:911.
Lexchin J. Different conclusions about memantine (letter). Canadian Family Physician
2007;53:403-4.
Mansfield P, Hoffman JR, Lexchin J. Educating health professionals about drug and
device promotion: authors’ reply (letter). PLoS Medicine 2007;4:393-394.
Lexchin J. Under-reporting of ADRs (e letter). CMAJ
http://www.cmaj.ca/cgi/eletters/175/5/449
Lexchin J. Rebuttal: are drugs too expensive in Canada. Canadian Family Physician
2006;52:841-2.
13
Lexchin J. Are drugs too expensive in Canada. Canadian Family Physician 2006;52:5735.
Biron P, Mintzes B, Lexchin J. Questions about Adderall XR (letter). CMAJ
2006;174:1303-4.
Lexchin J, Light D. Re: response to Light/Lexchin commentary (e letter). BMJ
http://bmj.bmjjournals.com.ezproxy.library.yorku.ca/cgi/eletters/331/7522/958
Lexchin J. Ejemplos foráneos en farmacia. Diario Medico, February 10, 2006:5.
Lexchin J. Is there still a role for spontaneous reporting of adverse drug reactions? CMAJ
2006;174:191-2.
Biron P, Mintzes B, Lexchin J. Adderall XR marketing status and Health Canada: a
disquieting about-face behind closed doors (e-letter). CMAJ available at
http://www.cmaj.ca/cgi/eletters/173/8/858
Lexchin J. A hypertensive snow bird (letter). CMAJ 2005;173:1357.
Lexchin J, Mintzes B. Summary basis of decision in context (letter). CMAJ
2005;172:1664-5.
Lexchin J. Prescribing errors (book review of Powerful Medicines). CMAJ
2005;172:229-30.
Lexchin J, Cassels A. Does the C in CME stand for Continuing or Commercial
(letter)? CMAJ 2005;172:160-1.
Lexchin J, Mintzes B. Transparency in drug regulation: mirage or oasis? CMAJ
2004;171:1363-5.
Lexchin J. New directions in drug approval. CMAJ 2004;171:229-30.
Lexchin J. Clinical trials register (letter). Lancet 2004;364:330.
Lexchin J. Stop the merry-go-round. Healthcare Papers 2004;4(3):29-34.
Lexchin J. The drug shortage that wasn’t. Canadian Healthcare Manager February
2004:31-2.
Light DW, Lexchin J. Will lower drug prices jeopardize drug research? A policy fact
sheet. American Journal of Bioethics In Focus 2004:4(1).
Lexchin J. The siren call of new drugs. Expert Review of Pharmacoeconomics and
Outcomes Research 2003;3:513-5.
Henry D, Lexchin J. Pfizer diflucan partnership program [letter]. Lancet 2003;361:72.
Lexchin J. Treating hyperkalaemia [letter]. Lancet 2003;361:616.
Mansfield P, Lexchin J, Vitry A, Doecke CJ, Svensson S. Drug advertising in medical
journals [letter]. Lancet 2003;361:879.
Henry D, Lexchin J. Patent law [letter]. Lancet 2003;361:1059.
Mintzes B, Lexchin J, Lippman A, Rochon Ford A. Too much disclosure of product
risks? [letter] CBC television, SOGC, and Diane-35. JOGC 2003;268-9.
Lexchin J. Statistics can affect treatment decisions. Can Fam Physician [letter]
2003;49:1587.
Lexchin J. Voluntary self-regulatory codes: what should we expect? American Journal of
Bioethics 2003;3(3):49-50.
Lexchin J. Inaccessibility of drug reports [letter]. CMAJ 2002;166:1251.
Lexchin J. Disclosure at Pfizer Canada [letter]. CMAJ 2002;167:847.
Lexchin J. New WHO/NGO database on drug promotion launched. Essential Drugs
Monitor No. 31, 2002:18-9.
14
Lexchin J. Journal supplements and evidence-based medicine [letter]. Can J Clin
Pharmacol 2001;8:162.
Lexchin J. Interactions between doctors and pharmaceutical sales representatives. Can J
Clin Pharmacol 2001;8:64-5.
Lexchin J, Mintzes B. Drug approval times [letter]. CMAJ 2000;162:1803-4.
Lexchin J. [letter]. American Journal of Managed Care 2000;6:1181-2.
Lexchin J. Promoting resistance. Essential Drugs Monitor No. 28&29, 2000:11.
Lexchin J. Double standards: double jeopardy. Pharmacoepidemiology and Drug Safety
2000;9:289-90.
Lexchin J. Plus ça change . . . Can Fam Physician 2000;46:532-6.
Lexchin J. Rethinking the numbers on adverse drug reactions [letter]. CMAJ
1999;160:1432.
Lexchin J. PMAC Code of Marketing Practices [letter]. CMAJ 1999;160:1556.
Lexchin J. Depression in the elderly [letter]. Ann Emerg Med 1999;33:724-5.
Lexchin J. Following the rules in marketing [letter]. CMAJ 1999;161:685-6.
Lexchin J. Don’t bite the hand that feeds you. West J Med 1999;171:238-239.
Lexchin J. Residents and pharmaceutical representatives [letter]. Can Fam Physician
1998;44:1448.
Lexchin J. Intellectual property rights and drug prices [letter]. Lancet 1998;352:582.
Lexchin J. Placing the ads [letter]. CMAJ 1998;159:920.
Lexchin J. Drug not considered a first-line agent [letter]. Can Fam Physician
1998;44:2376.
Lexchin J. Pharmaceutical industry. The Canadian Encyclopedia 1998 CD-ROM
Toronto: McClelland and Stewart, 1998.
Lexchin J. Consequences of direct-to-consumer advertising of prescription drugs.
Can Fam Physician 1997;43:594-6.
Lexchin J. Recent progress in drug advertising: rebuttal [letter]. Can Fam Physician
1997;43:1041-2.
Lexchin J. New CMA guide to drugs [book review of Canadian Medical Association
New Guide to Prescription and Over-the-Counter Drugs]. Can Fam Physician
1997;43:954.
Lexchin J. Doses of selected emergency drugs [letter]. Australian Prescriber
1997;20:57.
Lexchin J. Can a health care system change [letter]? Can Med Assoc J 1997;157:507-8.
Lexchin J. Putting a price on drugs [letter]. Can Med Assoc J 1997;157:869.
Mansfield P, Lexchin J. MaLAM: networking for scientific integrity in drug
promotion. Essential Drugs Monitor No. 24, 1997:5.
Lexchin J. Direct to consumer advertising of prescription drugs: the next steps. Can J
Clin Pharmacol 1996;3:65.
Lexchin J. Pharmacists can aid in improving prescribing [letter]. Can Med Assoc J
1996;155:1392.
Lexchin J. Inappropriate prescribing: how much are patients at fault [letter]? Can Fam
Physician 1996;42:1903-4.
Lexchin J. Breastfeeding still best [letter]. Can Fam Physician 1996;42:1669
1671.
Lexchin J. Costs of noncompliance disputed [letter]. Can Med Assoc J 1996;155:11-12.
15
Lexchin J. Controversial use of bromocriptine [letter]. Can Fam Physician
1996;42:1090-2.
Lexchin J. Payment equity for prescription drugs [letter]. Can Fam Physician
1996;42:404-5.
Lexchin J. Letter to the editor. J Emerg Med 1995;13:820.
Lexchin J. Debating benzodiazepine use [letter]. Can Fam Physician 1995;41:1293-5.
Lexchin J. Relations with the pharmaceutical industry [letter]. Can Med Assoc J
1994;151:413-4.
Lexchin J. Prescribing practices [letter]. Can Med Assoc J 1994;151:140.
Lexchin J. Debating the use of SMRs [letter]. Can Fam Physician 1994;40:1089.
Lexchin J. The management of acute otitis media [letter]. NZ Med J 1994;107:160.
Lexchin J. To whom is this book directed? [book review of Self-Medication, Product
Information, Vol 2, 4th ed]. Can Fam Physician 1994;40:1000,1041.
Lexchin J. Appetite stimulant claim deleted from label [letter]. Can Fam Physician
1994;40:20-1.
Lexchin J. Good introduction to complex topic [book review of Making Medicine,
Making Money]. Can Med Assoc J 1994;150:385-6.
Lexchin J. Safety last: the failure of the consumer health protection system in Canada
[book review]. Can Fam Physician 1993;39:2615.
Lexchin J. Why are we still poisoning the elderly so often? (editorial) Can Fam
Physician 1993;39:2298-2300.
Lexchin J. Psychotropic drug guidelines, 2nd ed [book review]. Can Fam Physician
1993;39:1475-6.
Lexchin J. Prescribing new drugs [letter]. Can Med Assoc J 1993;149:794-5.
Lexchin J. Treatment of Gaucher’s disease [letter]. New Engl J Med 1993;328:1566.
Lexchin J. Physicians and drug companies interact [letter]. Can Fam Physician
1993;39:1881-2.
Lexchin J. Treatment of Gaucher’s disease [letter]. New Engl J Med 1993;328:1566.
Lexchin J. Pharmaceutical ads in journals [letter]. Ann Intern Med 1992;117:617.
Lexchin J. NSAIDs and peptic ulcer [letter]. NZ Med J 1992;105:298.
Lexchin J. Prescription charges and drug utilisation [letter]. NZ Med J 1992;105:298.
Lexchin J. Use of methylphenidate for attention deficit hyperactivity disorder [letter].
Can Med Assoc J 1991;144:1209.
Lexchin J. Deciding whether to use cold remedies [letter]. Can Fam Physician
1991;37:832-3.
Lexchin J. Family physicians and prescribing factors [letter]. Can Fam Physician
1991;37:831.
Lexchin J. PAAB: a lesson in self-government [letter]. Can Med Assoc J
1991;144:844.
Lexchin J. A sample argument [letter]. Can Med Assoc J 1991;144:118.
Lexchin J. Resources for prevention of cardiovascular disease [letter]. NZ Med J
1990;103:593.
Lexchin J. Disinformation from pharmaceutical company representatives [letter]. Can
Med Assoc J 1990;143:370.
Lexchin J. Nonprescription cough and cold remedies [letter]. Can Med Assoc J
1990;143:175.
16
Lexchin J. Use of methylphenidate for attention deficit hyperactivity disorder [letter].
Can Med Assoc J 1990;143:171.
Lexchin J. The use of sedative-hypnotic drugs in a university teaching hospital [letter].
Can Med Assoc J 1990;142:1045.
Lexchin J. Canadian guide to prescription drugs [book review]. Can Fam Physician
1990;36:569-70.
Lexchin J. Treating attention deficit disorder [letter]. Can Fam Physician 1990;36:420
1.
Lexchin J. General practice formularies: the way ahead? (editorial) Can Fam
Physician 1989;35:1569-70.
Lexchin J. Declaration of vested interest [letter]. Lancet 1989;2:806.
Lexchin J. Drug economics in developing countries [letter]. Lancet 1989;2:678.
Lexchin J. Prescribing habits [letter]. NZ Med J 1989;102:260.
Lexchin J. Advertising drugs to the public [letter]. Lancet 1989;1:1392-3.
Lexchin J. Reducing drug costs [letter]. NZ Med J 1989;102:387.
Lexchin J. Antihypertensive drugs and advertising [letter]. NZ Med J 1988;101;805.
Lexchin J. Prescribing costs [letter]. NZ Med J 1988;101:616.
Lexchin J. Misuse of antibiotics in hospitals [letter]. NZ Med J 1988;101:548.
Lexchin J. Preferred medicines list [letter]. NZ Med J 1988;101:378.
Lexchin J. Introducing a new drug: an objection [letter]. Can Fam Physician
1988;34:1009-10.
Lexchin J. Drug promotion [letter]. NZ Med J 1987;100:754.
Lexchin J. Drug promotion [letter]. NZ Med J 1987;100:603.
Lexchin J. Advertisement scrutiny [letter]. Lancet 1987;1:1323-4.
Lexchin J. Office encounters in general practice [letter]. NZ Med J 1986;99:861.
Lexchin J. Pharmacists and family physicians [letter]. Can Fam Physician 1986;32:26.
Lexchin J. Diuretic-induced hypokalemia in hypertension [letter]. Can Med Assoc J
1985;133:183.
Lexchin J. Reader upset at CFPC's involvement in prescribing survey [letter]. Can Fam
Physician 1984;30:1454.
Lexchin J. Pharmaceutical advertising in medical journals [letter]. Can Med Assoc J
1984;131:544.
Lexchin J. Decline in pharmaceutical research [letter]. Can Med Assoc J 1984;130:554
5.
Lexchin J. The miracle of the empty beds: a history of tuberculosis
in Canada [book review]. Labour/Le Travailleur 1980;No. 6(Autumn):233-5.
Lexchin J. About those drug ads...[letter]. Can Fam Physician 1976;22:109-10.
On-line (peer reviewed)
Lexchin J. Generics competition in the EU, US and Canada. Politics of Medicine: Free
Online Encyclopedia. 2012. Available at:
http://www.politicsofmedicines.org/articles/generics-competition-in-the-eu-usand-canada
Lexchin J. Health Care Professionals. Politics of Medicine: Free Online Encyclopedia.
2012. Available at: http://www.politicsofmedicines.org/articles/health-care-
17
professionals
On-line (not peer reviewed)
Lexchin J. The Senate report on clinical trials – a tentative step forward. PharmaWatch
Canada 2012. Available at:
http://pharmawatchcanada.wordpress.com/2012/11/27/senate-report-on-clinicaltrials-a-tentative-step-forward/
Lexchin J. Vanishing drugs or vanishing drug shortages? PharmaWatch Canada 2012.
Available at: http://pharmawatchcanada.wordpress.com/2012/05/04/vanishingdrugs-or-vanishing-drug-shortages/
Lexchin J. Health Canada deficient in ensuring the safety of prescription medications.
PharmaWatch Canada. 2012. Available at:
http://pharmawatchcanada.wordpress.com/2012/01/12/health-canada-deficient-inensuring-the-safety-of-prescription-medications/
Lexchin J. Proposals for the evolution of CED policy. Health Technology Assessment
international: Access with Evidence Development Interest Sub-Group. December
21, 2011. Available at: http://htaiced.wordpress.com/2011/12/21/proposals-forthe-evolution-of-ced-policy/
Lexchin J. Little innovation, lots of promotion. CanadaValuesHealth.ca blog. Posted on
line 28 April 2009 at http://www.canadavalueshealth.ca/blog-en/
Pedagogical Materials
1998
1998
1997
Lexchin J. Heat related illness. In Fulton L et al (eds). Introduction to
emergency medicine. Divisions of Emergency Medicine, Faculty of
Medicine, University of Toronto
Lexchin J. Cold related illness. In Fulton L et al (eds). Introduction to
emergency medicine. Divisions of Emergency Medicine, Faculty of
Medicine, University of Toronto
Lexchin J (ed). Clinical epidemiology and research design for emergency
medicine residents. Ottawa: Canadian Association of Emergency
Physicians
Other:
Commissioned Reports
Wiktorowicz M, Lexchin J, Moscou K, Silversides A, Eggertson L. Keeping an eye on
prescription drugs, keeping Canadians safe: active monitoring systems for drug
safety and effectiveness in Canada and internationally. Health Council of Canada,
2010. Available at:
http://www.healthcouncilcanada.ca/docs/rpts/2010/DSE/DSE_E_FINAL_Nov17.
pdf
Wiktorowicz M, Lexchin J, Paterson M, Mintzes B, Light D, Morgan S, Holbrook A,
Tamblyn R, Zaki E, Moscou K. Research networks involved in post-market
pharmacosurveillance in the United States, United Kingdom, France, New
18
Zealand, Australia, Norway and European Union: lessons for Canada. Canadian
Patient Safety Institute, 2008. Available at:
http://www.patientsafetyinstitute.ca/uploadedFiles/Research/Post
Marketing%20Pharmacosurveillance%20Final%20Report.pdf
Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug promotion: what we know, what
we have yet to learn. World Health Organization/Health Action International,
2004.
Sanger M, Sinclair S, Campbell B, Blouin C, Foster J, Labonte R, Lexchin J,
Shrybman S. Putting health first: Canadian health care reform, trade treaties and
foreign policy. Summary Report for the Commission on the Future of Health Care
in Canada, October 2002.
Lexchin J, Caygill D. Report to the [New Zealand] Minister of Health and the
Health Funding Authority on the proposed revisions to PHARMAC’s operating
policies and procedures. September 2001.
Reports
Lexchin J. Who’s calling the tune: harmonization of drug regulation in Canada. Ottawa:
CCPA, 2011.
Lexchin J. Drug safety and Health Canada: going, going … gone? Ottawa: CCPA, 2009.
Lexchin J. Canadian drug prices and expenditures: some statistical observations and
policy implications. Ottawa: CCPA, 2007.
Lexchin J. 50 years of waiting for Pharmacare is long enough. In: Public health care is
best! Don’t let privatization creep in. Ottawa: Canadian Federation of Nurses
Unions, 2005.
Lexchin J. Transparency in drug regulation: mirage or oasis? Ottawa: CCPA, 2004.
Lexchin J. Intellectual property rights and the Canadian pharmaceutical marketplace:
where do we go from here? Ottawa: CCPA, 2003.
Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP. Drugs in the
news: how well do Canadian newspapers report the good, the bad and the ugly of
new prescription drugs. Ottawa: CCPA, 2003.
Lexchin J. Globalization, trade deals and drugs: heads industry wins, tails Canada loses.
Canadian Centre for Policy Alternatives, Briefing Paper Series 2001;2(8):1-14.
Lexchin J. A national pharmacare plan: combining efficiency and equity. Ottawa:
Canadian Centre for Policy Alternatives, March 2001.
Lexchin J. Pharmaceuticals, patents and politics: Canada and Bill C-22. Ottawa:
Canadian Centre for Policy Alternatives, February 1992.
Popular
Lexchin J. Find a home for pricey ‘orphan drugs’. Toronto Star 2011 Jan. 27.
Guyatt G, Lexchin J, Baird P. B.C. must reverse course on drug reviews. Times Colonist
2010 Dec. 8.
Lexchin J. Cost of brand-name drugs, not generics, needs cutting. CCPA Monitor
2010;17(2):23.
Lexchin J. Ontario’s big pharma drug war. The Bullet (e bulletin no. 342), April 2010.
19
Lexchin J. Pharma needs to be more upfront about drug risks [letter]. Medical Post 2008
November 11.
Lexchin J. More people exposed to unsafe drugs before withdrawal. CCPA Monitor
2008;15(5):10-11.
Lexchin J, Gagnon, MA. Study authors assail column as the real flawed thinking [letter].
Medical Post 2008 April 11.
Lexchin J. Poking holes in drug comparison study [letter]. Medical Post 2008 February
22.
Lexchin J. It’s time to end Canadians’ long wait for Pharmacare. CCPA Monitor
2007;14(7):1, 6.
Lexchin J. Drug research is now done mainly to protect profits, not public health. CCPA
Monitor 2007;14(1):14-16.
Lexchin J. Responses and letters. Literary Review of Canada. December 2006:30-1.
Lexchin J. Risks and benefits of the profit motive in the pharmaceutical industry. July 11,
2006. Published on-line at AgoraVox
< http://www.agoravox.com/article.php3?id_article=4957>.
Lexchin J. Think you can obtain information from Health Canada? Forget it! CCPA
Monitor 2006;12(9):29.
Lexchin J. Three thumbs down on private health care [letter to the editor]. National Post
2006, Feb. 22:A13
Lexchin J. . . . but newer isn’t better. National Post 2005 April 8: FP 19.
Lexchin J. Letter to the editor. Literary Review of Canada 2004;12(10):30.
Lexchin J. Lack of transparency in drug regulation leaves safety in doubt. CCPA Monitor
2004;11(4):13.
Cassels A, Lexchin J. We can swing no-frills pharmacare. Vancouver Sun 2004 Sept. 1.
Lexchin J. Drug dilemma. Medical Post 2002 July 30:13.
Lexchin J. Profit-fixated drug firms fund profit-boosting ‘research.’ CCPA Monitor
2002;8(9):24.
Lexchin J. Federal gov't's flawed drug policies exposed by anthrax scare. CCPA
Monitor 2002;8(7):10.
Lexchin J. Prescriptions for profit. Literary Review of Canada March 2001:14-17.
Lexchin J. Drug multinationals: the bitterest pill [book review of Prescription Games:
Money, Ego and Power Inside the Global Pharmaceutical Industry]. Globe and
Mail 2001(June 2):D5.
Lexchin J. Patents on AIDS drugs are patently unnecessary. Globe and Mail 2000 Sept
4:A13.
Lexchin J. B.C., Ontario try different ways to tackle drug costs. CCPA Monitor
1996;3(3):7.
Lexchin J. Silencing the whistle blowers. Outlook 1999;37(5):12, 27.
Lexchin J. What’s a drug company to do? DES Action Canada Newsletter 1999; Issue
58:1-3.
Lexchin J. How safe are prescription drugs? Literary Review of Canada
1998;7(4):21-4.
Lexchin J. ‘Shared responsibilities, shared vision’: a critique. Canadian Women’s
Health Network 1998;1(4):4-5.
Lexchin J. Facing down the drug cost monster. Canadian HR Reporter June 1,
20
1998:G8-G9.
Lexchin J, North P. OMA perspective on comparative advertising of pharmaceutical
products. OMA Review 1998;(5):25-7.
Lexchin J. National pharmacare conference. Medical Reform March 1998:1-3.
Lexchin J. Report on national pharmacare conference, Saskatoon. OMA Drug Report
No. 60, March 1998:1-2.
Lexchin J. Update on C-91. Medical Reform 1997;17(2):4-5.
Lexchin J. Just how much does it really cost to develop a drug? Toronto Star 1997
February 27:A29.
Lexchin J. Pharmacare would cut individual and overall drug costs. CCPA Monitor
1997;4(4):17.
Lexchin J. Pharmaceutical policy and politics: dangerous dosage. Outlook
1997;35(4):10,11,21.
Lexchin J. Pharmaceutical policy and politics. Medicare Monitor 1996;11(2):3-4.
Lexchin J. Drug firms wallow in profits—but they want more. CCPA Monitor
1996;3(6):13.
Lexchin J. Eves’ prescription for inequity. Toronto Star 1996 January 5:A23.
Lexchin J. Why poison the elderly? HAI News 1994; No. 76 (Apr):1,2,11.
Lexchin J. We need a war on legal drugs. Toronto Star 1994 June 13:A15.
Lexchin J. MDs’ abuse of drug samples a very discouraging practice [letter]. Med Post
1993 Oct 5:11.
Lexchin J. Studies show promotion of drugs increases their use [letter]. Med Post 1991
Dec 17:15.
Lexchin J. Price of drugs [letter]. Globe and Mail 1991 Sept 2:A10.
Lexchin J. More competition leads to lower drug prices [letter]. Medical Post 1991 Apr
16:15.
Lexchin J. Double standards in drug promotion. INRUD News 1991; 2(2):3.
Lexchin J. Patented medicines review board. Medical Reform 1991;11(3):3-4.
Lexchin J. Drug lobby hasn't finished with Canada yet [letter]. Toronto Star 1990 Sept
19:A25.
Lexchin J. Pharmacare: did the royal commission reach its goal? InforMed
1990;5(Mar):3.
Lexchin J. First do no harm. Infact Canada Newsletter Fall 1989:2-3.
Lexchin J. Let's plug the gaps in Ottawa's drug safety laws. Toronto Star 1989 Sept
26:A21.
Lexchin J. The pharmaceutical industry in Canada. HAI News 1989; No.46
(Apr):1,2,11.
Lexchin J. Canadian research loses in Connaught lab sale. Toronto Star 1989 May
26:A19.
Lexchin J. Is anyone reading the fine print? Globe and Mail 1989 Mar 20:A7.
Lexchin J. Pushing pills: who's to blame for so much poor prescribing? Globe and Mail
1988 Dec 13:A7.
Lexchin J. A need to cut red tape without cutting corners. Globe and Mail 1988 July
7:A7.
Lexchin J. The price of treating AIDS. Globe and Mail 1988 Mar 1:A7.
Lexchin J. Patent system can impede drug research [letter]. Toronto Star 1987 Jul
21
16:A18.
Lexchin J. Drug pushers go for big profits. Canadian Dimension 1987;21(Jul/Aug):29
30.
Lexchin J. Your money or your life: prescription drugs...the cost of being ill. The
Anglican Magazine 1987;98(May):2-4.
Lexchin J. Malfunction in minister's memory [letter]. Medical Post 1987 March 17:14.
Lexchin J. A prescription for profits. Now 1986 Dec 11-17:9,15.
Lexchin J. Inside dope [letter]. This Magazine 1986-7;20(Dec/Jan):12-13.
Lexchin J. In bed together. New Internationalist 1986; Nov:20.
Lexchin J. Muddy field, muddy thinking [letter]? Medical Post 1985 Feb 19:8.
Lexchin J. Pushing pills for profit in Canada. Goodwins 1984-5;2(Winter):9,38.
Lexchin J. The generic drug controversy. Canadian Jewish Outlook 1985;23(Mar):7-8.
Lexchin J. Is Med Post carrying banner for drug firms...[letter]. Medical Post 1982 Oct
5:21.
Lexchin J. Getting doctored--a review. Canadian Dimension 1980;17(Aug):54-5.
Lexchin J. Naylor nailed [letter]. This Magazine 1978;12(2):33.
Lexchin J. Drug costs could be halved: how the drug industry makes sure they aren't.
Canadian Dimension 1971;8(Aug):12-24.
Lexchin J. The drug industry prostitutes itself for profit. The Varsity 1970 Dec 11:4-5.
CONFERENCE PRESENTATIONS
2012
2012
2011
2011
2011
2010
2010
Underuse of classic drugs. Missing the target: when practitioners
harm more than heal, Washington
Implications of the difference between general practitioners’
perceptions of the encounters and the reality of the quality of
information transmitted. Pharmaceutical Sales Representatives and
Patient Safety: A Workshop/Consultation on the Implications for
Policy and Practice, Vancouver
Free trade and intellectual property rights: implications for the
Canadian pharmaceutical environment, The Influence of Trade and
Trade Policy on Health, American Public Health Association
annual meeting, Washington (peer reviewed)
A comparison of journal advertising in three countries,
Pharmaceutical Policy Research Collaboration meeting, Halifax
Abbott J, Lexchin J, Wiktorowicz M, Majunder S. Drug safety and
effectiveness in Canada: issues, challenges, and new approaches.
CADTH Symposium, Vancouver, April 5 (peer reviewed)
Canada’s access to medicines regime: social justice attempted &
subsequent failure, American Public Health Association Annual
Meeting, Denver (peer reviewed)
Why is regulation of promotion necessary: results of a systematic
review. To Do No Harm: Regulation of Pharmaceutical Promotion
and the Protection of Patient Health. Toronto 2010 Plenary
speaker, Do those who have the gold make the rules: industry and
22
2010
2010
2010
2010
2009
2009
2009
2009
2009
2008
2007
2007
2007
2007
(un)biased information, Quality Information for Quality Use of
Medicines, Kazan State Medical Academy, Kazan, Russia
Industry and (un)biased information, Pharmaceutical Promotion
and Its Impact on Public Health Regulation of Promotion, World
Health Organization, Health Action International in collaboration
with Drug Agency of Ministry of Health of The Republic of
Moldova, Chisinau, Moldova
Drug companies and medical knowledge, Prescription for Conflict:
Should Industry Fund Continuing Medical Education? Washington
DC.
CME and the pharmaceutical industry: do those who have the gold
make the rules, Canadian Association of Emergency Physicians
annual conference, Montreal
Marketing before patenting: implications for price controls in
Canada, Canadian Association for Health Services and Policy
Research, Toronto (peer reviewed)
Drug safety and Health Canada: going, going … gone?
Therapeutics Initiative and Centre for Health Services and Policy
Research, Seminar Vancouver
One step forward, one step sideways: expanding research capacity
for neglected diseases, American Public Health Association
Annual Meeting, Philadelphia (peer reviewed)
Company pricing strategies for multiple dose prescription
medications: an analysis of the Ontario Drug Benefit Formulary,
Pharmaceutical Policy Research Collaboration meeting, Ottawa
Invited speaker, Drug safety and Health Canada: going, going …
gone? Tracing Pharmaceuticals in South Asia, Edinburgh
Invited speaker, The secret things belong unto the lord our God:
secrecy in pharmaceutical regulation, Workshop on Reassessing
the Governance of Clinical Trials: Preventing Real-World Risks at
the Gate, Halifax
Invited speaker, One step forward, one step sideways – expanding
research capacity, The Science and Politics of Neglected-Disease
Research: Philosophical, Bioethical and Sociological Perspectives
on International Health Inequalities. Brocher Centre, Geneva.
Clinical trials in Canada: an exploratory review at Conference on
pharmaceutical policy analysis 2007. Zeist, The Netherlands (peer
reviewed)
The Common Drug Review: an international comparison,
CAHSPR annual meeting, Toronto (peer reviewed).
Intellectual property rights and access to medicines, 5th Annual
Global Health Research Conference, Toronto
Whose evidence, what kind of practice: profits, research and
medical practice, Annual meeting Canadian Agency for Drugs and
Technologies in Health, Ottawa.
23
2006
2006
2006
2006
2006
2006
2006
2006
2005
2005
2005
2005
2005
2005
2004
2004
2004
New approaches to improve development and access to AIDS
drug, American Public Health Association annual meeting, Boston
Panelist, What is government’s role? Access to Medicines as a
Human Right, Munk Centre for International Studies, Toronto
Conflicts of interest and outcomes of reviews, North American
Conference on Systematic Reviews: Encompassing Diversity in
Systematic Reviews, Baltimore
Implications of pharmaceutical company funding of clinical
research, Society for Socialist Studies, York University
The long road to pharmacare, Canadian Association for Population
Therapeutics Annual Meeting, Toronto
Doctors and drug companies: too close for comfort? Gender, Child
Survival and HIV/AIDS: From Evidence to Policy, York
University
Panelist, Style or substance: the lifestyle drug continuum,
Therapeutic Insight 2006, Boston
Bigger and better: how Pfizer redefined sexual dysfunction,
Inaugural Conference on Disease-Mongering. Newcastle, Australia
Panelist, After Vioxx whither drug safety in the U.S., American
Public Health Association annual meeting, Philadelphia
Plenary speaker, Doctors and the pharmaceutical industry: too
close for comfort? Putting Evidence into Practice 3rd Annual
Conference, Edmonton
Plenary speaker, Are We Living in an Evidence B(i)ased World,
Combined Medicine Grand Rounds and Putting Evidence into
Practice 3rd Annual Conference, Edmonton
Invited speaker, Secrecy in drug research, Academic Freedom
Post-9/11, Harry Crowe Foundation, Toronto
Invited speaker, Can we trust our research and our journals,
Michigan State Medical Society, Ninth Annual Bioethics
Conference, Traverse City, Michigan
Panelist, Roundtable: Modernizing Health Care: Perils and
Prospects. Canadian Political Science Association, Congress of the
Social Sciences and Humanities, London, Ontario
Keynote speaker, Direct-to-consumer advertising of prescription
drugs and safe use of medicince: an oxymoron, Australian
Pharmaceutical Sciences Association conference, Melbourne
Keynote speaker, Canadian prescribing practices: where do we go
from here, Australian Pharmaceutical Sciences Association
conference, Melbourne
Invited presentation, Improving the structure, quality and
efficiency of pharmaceutical research, Avedis Donabedian Award
Session: Sid Wolfe and the Public Citizen Health Research Group,
American Public Health Association Annual Meeting, Washington
D.C.
24
2004
2004
2004
2004
2004
2004
2004
2003
2002
2002
2001
2001
2001
1998
Invited presentation, How does Canada control costs and what are
the effects? APHA Special Session on Medicare Drug Benefit,
Part II, American Public Health Association Annual Meeting,
Washington D.C.
Invited presentation, Do lower drug prices hurt health care in
Canada at Controlling Drug Prices, Home and Abroad: Beyond
Formularies and Importation, American Public Health Association
Annual Meeting, Washington D.C.
Invited presentation, Implications of pharmaceutical industry
sponsorship of clinical research, Critical Perspectives on
Pharmaceutical Companies, American Public Health Association
Annual Meeting, Washington D.C.
Invited speaker Controlling drug costs: learning from Canada, U.S.
and Canadian pharmaceutical policy: a tale of two countries,
Connecticut Journal of International Law Symposium, Hartford
Invited speaker, Pharmaceutical promotion in another cold country
(Canada) at Drug Marketing – Promoting Rational Drug Use?
Stakes (Finnish National Research and Development Centre for
Welfare and Health), Helsinki
Invited speaker, New Directions in Canadian Drug Regulation:
Whose Interests are Being Served? Health democracy and the
globalised pharmaceutical industry: exploring the politics of drug
regulation internationally and in Ireland, Cork. (peer reviewed)
Key note address, Advertising antibiotics – promoting resistance
SWAB Symposium, The Netherlands.
Invited presentation, Industry sponsorship of research and
educational events: risks and benefits, Canadian Association of
Emergency Physicians annual meeting, Winnipeg.
Invited paper, Canada, globalization and health care, American
Public Health Association annual meeting, Philadelphia.
Drugs in the news: how well do Canadian newspapers report the
good, the bad and the ugly of new prescription drugs? Canadian
Science Writers Association Annual General Meeting, May 2002,
Toronto.
Invited paper, TRIPS and drugs: National and international
experience, Centre for Health Services and Policy Research, 14th
Annual Health Policy Conference—Trading Away Health?
Globalization and Health Policy, Vancouver.
Invited paper, Canada, free trade agreements and drug costs,
American Public Health Association annual meeting, Atlanta.
(peer reviewed).
Invited speaker, Ethical behaviour of pharmaceutical corporations,
Global Scenarios Workshop, Corporation of the Future, Shell,
London, U.K.
Invited paper, The pharmaceutical industry and physicians: a
healthy relationship, Health Action International Seminar, The
25
1998
1998
1997
1997
1996
1996
1995
1995
1993
1992
1989
1987
1985
1985
Ties that Bind? Weighing the Risks and Benefits of
Pharmaceutical Industry Sponsorship, Paris.
Invited paper, Promotion by the pharmaceutical industry, Reunion
Internactional sobre Medicamentos Genericos, Mexico City.
Invited speaker, Challenges for a pharmacare plan, National
Pharmacare Conference, Saskatoon.
Development and implementation of a course for emergency
medicine residents in clinical epidemiology and research design,
Australasian College of Emergency Medicine 14th Annual
Scientific Meeting, Adelaide, Australia. (peer reviewed)
Invited paper, National pharmacare: what are the issues, Second
National Conference on Cost-Effective Drug Therapy, Toronto.
Invited speaker, Pharmaceuticals: a study in cost shifting, Centre
for Health Economics and Policy Analysis, Annual Conference,
Toronto.
Beyond Bills C-22 and C-91: Coming issues in pharmaceutical
policy and politics. Sociology of Health Care Systems, Canadian
Sociology and Anthropology Association, 31th Annual Meeting,
St. Catharines. (peer reviewed)
Invited paper, Control of pharmaceutical promotion, Brazilian
Society for Monitoring of Medications, 3rd Congress, Sao Paulo.
Cost effective pharmaceutical care for the elderly and the
formation of pharmaceutical policy in Canada. Drugs and Health
Care Systems in Canada, Canadian Sociology and Anthropology
Association, 30th Annual Meeting, Montreal, 1995. (peer
reviewed)
Poster session: An Assessment of the Methodologic Quality and
Relevance of References in Pharmaceutical Advertisements in a
Canadian Medical Journal, Canadian Pharmacoepidemiology
Forum, Toronto
Public Good [Health] or Private Profits: Focus on
Pharmaceuticals, Women, Racial Minorities, Medicine and Health,
Saskatoon
Responses to Physician's Concerns of Adverse Drug Interactions:
Comparing the Behaviour of Generic and Brand Name
Manufacturers at Research and the Health Policy Process, 2nd
Annual Health Policy Conference, Hamilton
Prescribing in Canada freestanding paper, 25th Annual Scientific
and Business Meeting, Ontario Chapter College of Family
Physicians of Canada, Toronto
The Portrayal of the Elderly in Drug Advertisements, Drugs and
Geriatric Care, Seventh Annual Conference on Drugs and Geriatric
Care, Toronto
Government Control and Regulation of Reproductive Drugs and
Devices at Who's In Control? Legal Implications of Reproduction
26
and Technology. Sixth National Biennial Conference of the
National Association of Women and the Law, Ottawa
POSTER PRESENTATIONS (Refereed)
April 2011
May 2010
Nov. 2009
February 2006
Wiktorowicz M, Majunder S, Lexchin J. Post-market surveillance
of drug safety and effectiveness: international approaches and
lessons for Canada at Canadian Association for Population
Therapeutics, Vancouver
Lexchin J. Surrogate outcomes, clinical outcomes and drug safety,
Canadian Association for Health Services and Policy Research,
Toronto
Lexchin J. Drug advertisements in medical journals: education or
deception, American Public Health Association Annual Meeting,
Philadelphia
Lexchin J. Comparison of new drug availability in Canada and the
United States, Centre for Health Services and Policy Research
Annual Conference, Vancouver
BRIEFS TO GOVERNMENT COMMITTEES AND OTHER ORGANIZATONS
May 2012
April 2012
May 2007
June 2006
April 2006
Nov. 2005
May 2005
May 2005
April 2005
Feb. 2005
Lexchin J. Presentation to Standing Senate Committee on Social
Affairs, Science and Technology on Clinical Trials
Lexchin J. Presentation to Standing Committee on Health of the
House of Commons on Drug Shortages
Lexchin J. Presentation to Standing Committee on Health of the
House of Commons on Common Drug Review
Lexchin J, Kalant N. Brief to Social Affairs Committee Ontario
Legislature on Bill 102 (on behalf of the Medical Reform Group)
Lexchin J. Brief on Direct-to-Consumer Advertising to Ministry of
Health, New Zealand
Lexchin J. Presentation to the Standing Committee on Health of
the House of Commons on pharmaceutical policy (on behalf of the
Medical Reform Group)
Mansfield P, Lexchin J, Raven M, Jureidini J, Faggotter R, Burn
R. Submission to Medicines Australia Review of the Code of
Conduct
Lexchin J. Presentation to Standing Committee on Health of the
House of Commons on Bill C-420
Lexchin J, Ford AR (on behalf of Women and Health Protection).
Brief on Consumer Advertising Guidelines for Marketed Health
Products to Advertising Standards Canada
Written testimony to US Senate Committee on Health, Education,
Labor and Pensions. Hearing: Drug Importation: Would the Price
be Right?
27
January 2005
October 2003
January 2001
February 1998
March 1997
November 1992
September 1988
May 1987
May 1987
January 1987
August 1984
Light D, Lexchin J. Cost of innovation and value for money.
Memorandum to the Health Select Committee of the British House
of Commons on The Influence of the Pharmaceutical Industry
Lexchin J, Pellizzari R, McIsacc B. Brief on behalf of the Medical
Reform Group of Ontario to the Standing Committee of the House
of Commons on Health
Lexchin J. Brief on Direct-to-Consumer Advertising to Ministry of
Health, New Zealand
Lexchin J. Patented Medicine Prices Review Board discussion
paper.
Lexchin J. Need not greed: a brief to the House of Commons
Standing Committee on Industry Review of Bill C-91.
Lexchin J. Brief of the Canadian Health Coalition and the Medical
Reform Group to the House of Commons Committee on Bill C-91.
Lexchin J. Prescribing in Canada: a review of the literature.
Medical Reform Group of Ontario brief to the Pharmaceutical
Inquiry of Ontario.
Lexchin J. Medical Reform Group of Ontario Brief to the Senate
Committee on Bill C-22.
Lexchin J. Health Action International/Canada Brief to the Senate
Committee on Bill C-22.
Lexchin J. Medical Reform Group of Ontario Brief to the
Parliamentary Committee on Bill C-22.
Lexchin J. Medical Reform Group Brief to Commission of
Inquiry on the Pharmaceutical Industry.
GRANTS
2012
2012
2012
2010
2010
Assessing the ethics of the dominant business model in the
Canadian pharmaceutical sector; tackling institutional corruption
through regulatory reforms. CIHR $84,204 (2 years), collaborator
(PI: Marc-Andre Gagnon, Jillian Clare Kohler)
Planning the evaluation of medication review in emergency
department patients. CIHR $24997 (1 year), PIs: Corinne Hohl,
Joel Lexchin and Boris Sobolev
Pharmaceutical Sales Representatives and Patient Safety:
exploration of physician experiences in three countries and
implications for regulatory policy, CIHR $154,183 (2 years), PIs:
Barbara Mintzes, Joel Lexchin
Re-imagining long-term residential care: an international study of
promising practices, Major Collaborative Research Initiatives,
Social Sciences and Humanities Research Council $2.498 million
(7 years), Co-applicant (PI: Pat Armstrong)
Discussion Paper on Drug Safety and Effectiveness in Canada and
Abroad, Health Council of Canada $37,500 (2 months), PIs: Mary
Wiktorowicz and Joel Lexchin
28
2009
2009
2009
2009
2009
2008
2006
2006
2006
2006
2005
2005
2003-2004
2002-2003
2001-2002
1999-2000
1998-1999
Meetings, Planning and Dissemination Grant: Health Services and
Policy Research, CIHR $17,500 (12 months), PI
Travel grant, Faculty of Health, $1000
Public Opinions on the Ethics of Physician-Pharmaceutical
Industry Interactions, CIHR $109,405 (18 months), Co-applicant
(PI: Anne Holbrook)
Comparison of journal ads in Australia, Canada and the United
States, Faculty of Health minor research grant $3000
CIHR/Health Canada team in policies for equitable access to
medications, CIHR $1,494,565 (5 years), Co-applicant (PI: Steve
Morgan)
Pharmaceutical sales representatives and patient safety:
comparative cross-sectional survey, CIHR $282,238 (2 years),
PIs: Barbara Mintzes, Joel Lexchin
A Synthesis of What We Need and What Works re Post-Marketing
Surveillance of Drug Safety and Effectiveness, CPSI
$54,879.00 (6 months), PIs: Mary Wiktorowicz, Joel Lexchin
Testing pharmaceutical policy to improve global health: An
evaluation of bill C-9, an act to amend the patent act and food and
drugs act, CIHR $138,632 (4 years), PIs: Jillian Clare Cohen,
James Orbinski, Co-applicants: Joel Lexchin, Noah Novogrodsky
International survey of strategies for post-market
pharmacosurveillance: lessons for Canada, CIHR $113,416 (2
years), PIs: Mary Wiktorowicz, Joel Lexchin
Atkinson Research Incentive Award $200
Evaluation of the integrity of clinical research in Canada, CIHR
$225,023 (2 years), PI: Paula Rochon, Co-PIs: An-Wen Chen,
Lorraine Ferris, Jennifer Gold, John Hoey, Joel Lexchin, James
Maskalyk, David Moher, David Streiner, Nathan Taback, Marleen
van Laethem
SSHRC Minor grant, $1100
Principal investigator: G. Guyatt. Co-principal investigator: J.
Lexchin. Comparison of health outcomes in Canada and the
United States: a systematic review. Atkinson Foundation, $60,000.
Purpose: Operating grant
Atkinson Faculty, Minor Research Grant $1600.
Globalization and health, P.I. B. Campbell Co-investigators C.
Blouin, J. Lexchin, R. Labonte, M. Sanger, S. Shrybman,
Commission on the Future of Health Care in Canada $95,000,
Purpose: Operating grant
Development of a database on pharmaceutical promotion, P.I. J.
Lexchin, World Health Organization, $45,000, Purpose: Operating
grant
Drug Plan Policies that optimize the use of prescription drugs and
health outcome, P.I. J. Lexchin, Seniors Independence Research
29
Program National Consensus Process, $8,333, Purpose: Operating
grant
CONTRIBUTIONS TO THE PROFESSION
Abstract reviewing for conferences
2010
2007
Abstract review for Access topic track, Third International
Conference for Improving Use of Medicines, April 10-14, 2011,
Alexandria Egypt (70 abstracts reviewed)
Abstract reviewer for International Health Section, American
Public Health Association annual meeting
Conference Chairing
2008
2001
Chair, opening session, Health Action International seminar
Clinical Trials on Trial, Berlin
Chair, Health Action International/Medico International Seminar
Sustaining Access to Medicines in Europe: The Coming Crisis
Frankfurt
Conference Organization
2010
2009-2010
2009-2010
Planning committee, Access topic track, Third International
Conference for Improving Use of Medicines, April 10-14, 2011,
Alexandria Egypt
Co-organizer (with Annelies den Boer, WEMOS), International
Expert Working Group on New Models for Funding Clinical
Trials, Nov. 22-23, 2010, Amsterdam
Planning committee, Selling Sickness conference, Oct. 7-8, 2010,
Amsterdam
Offices in Professional Organizations
1998-99
1995-97
1995-97
Chair, Drugs and Pharmacotherapy Committee, Ontario Medical
Association
Member, Ontario Medical Association, Committee on Drugs and
Pharmacotherapy
President, Medical Lobby for Appropriate Marketing
Consultancies, Advisory Committees
2011
Focus group member, Canadian Nurses Association National
Expert Commission
30
2011 2010 - 2011
2009-2010
2009-
2009-
20092009
2008-
2008-
2007
2006 2006 - 2012
2005
2005 - 2010
2005 - 2006
20032003
2002
2002
2001 2000
2000
1999-2005
1996
Chair, Health Action International – Europe Association Board
Advisory committee, DocInfo project out of Dalhousie University
Reviewer, CIHR Catalyst Grant: Drug Safety Efficiency Network
Competition
International consultative committee. Patient and consumer groups
at the European Medicines Agency. Health Action International,
Amsterdam
International consultative committee. Measuring the Impact of
pharmaceutical promotion regulation. Health Action International.
Amsterdam
Academic editor, PLoS One
Part of lobby team from Health Action International at World
Health Assembly
Expert Advisory Panel, The assessment of effectiveness of
medicines promotion control measures: methodology
development, Health Action International
Advisory Board, Ethical and administrative control of clinical
research financed by Academy, Medical Research Council,
Finland
Invited participant, Tracing Pharmaceuticals in Southeast
Asia, Centre for International Public Health Policy, University of
Edinburgh
Editorial board, Healthcare Policy
Editorial board, Journal of Public Policy and Marketing
Schedule A expert advisory committee to Health Canada
Reviewer for Media Doctor Canada
Advisory committee, Psychotropic drug use as a gender-sensitive
marker of emotional health for women, Health Canada sponsored
project
Steering committee, Women and Health Protection
Consultant for Our Bodies Our Selves (35th Anniversary Edition)
Commission on the Future of Health Care in Canada. Reviewed
paper on Pharmacare produced by Canadian Health Services
Research Foundation
World Health Organization. External reviewer WHO Guidelines
for Consumers on Proper Use of Traditional Medicine and
Complementary/Alternative Medicine
Board member, PharmaWatch
New Zealand Health Funding Authority. Reviewed proposed
changes to Operating Policies and Procedures of PHARMAC
(Pharmaceutical Management Committee)
Australian National Prescribing Service. Reviewed draft
evaluation plan for Australian National Prescribing Service
Member, Health Action International – Europe, Association Board
Member of Education Working Group, Ontario Round Table on
Appropriate Prescribing
31
1997
1996
1996-1998
1996-1997
1995-2000
1995
1994
1994-1995
1994-1997
1994-1995
1994
1993-1994
1993-present
1993
1992-1994
1992-1993
1992-1993
1992-1993
1992
1990-1991
1990-1994
1990-1995
Ontario Medical Association representative to Health Canada
Consultation Workshop on Comparative Advertising of
Prescription Drugs, Aylmer, Quebec
Ontario Medical Association representative to Health Canada
Consultation Workshop on Direct to Consumer Advertising of
Prescription Drugs, Aylmer, Quebec
Member of Reference Standard Detail Committee of Ideal Detail
Study, Chief Investigator Dr. David Strang, McMaster University
Member of advisory panel for Consumers’ Association of Canada
research project: Consumers and Bill C-91
Consultant, Ontario Drug Quality and Therapeutics Committee
Chapter reviewer for: Self-Medication, Reference for Health
Professionals, Canadian Pharmaceutical Association
Member, Ontario Ministry of Health Nurse Practitioner
Advisory Group Concerning NPs with Prescribing Authority
Member, Canadian Medical Association Physician Prescribing
Practices Workshop Planning Committee
Member, Ontario Medical Association, Committee on Drugs
and Pharmacotherapy
Member, Ontario Federation of Labour Health Research Project,
Research Advisory Committee
Chair, Ad-Hoc Committee on the Relationship Between the
Emergency Residency Programs at the University of Toronto and
the Pharmaceutical Industry
Contributor, Cochrane Field Co-ordination in Accident and
Emergency Medicine
Member, Pharmacy and Therapeutics Committee, University
Health Network
Invitee, Workshop on National Pharmaceutical Strategy, Health
Protection Branch
Member, Ontario Drug Quality and Therapeutics Committee
Consultant to University of Toronto Health News for emergency
related topics
Member, Pharmaceutical Investment and Development Working
Group, Drug Programs Reform Secretariat Advisory Council,
Ontario Ministry of Health
Member, Drug Programs Reform Secretariat Advisory Council,
Ontario Ministry of Health
Invited Participant, Ontario Ministry of Health Invitational
Drug Utilization Review Workshop, Toronto
Member, Task Force On The Relationship Between Physicians and
the Pharmaceutical Industry, College of Physicians and Surgeons
of Ontario
Member, International Secretariat for Medical Lobby for
Appropriate Marketing (MaLAM)
Member, Committee to Develop European General Practice
32
Formulary
Manuscript Reviewing
American College of Physicians – Physicians Information and Education Resource
American Journal of Bioethics
American Journal of Managed Care
Annals of Internal Medicine
Archives of Internal Medicine
BMC Family Medicine
BMC Health Services Research
BMC Public Health
British Medical Journal
Canadian Family Physician
Canadian HIV-AIDS Legal Network
Canadian Journal of Clinical Pharmacology
Canadian Journal of Emergency Medicine
Canadian Journal on Aging
Canadian Medical Association Journal
Canadian Public Policy
Disease Management and Health Outcome
Drug Safety
Expert Review of Pharmacoeconomics and Outcomes Research
Globalization and Health
Health and Canadian Society
Health Affairs
Health Policy
Health Reports
Healthcare Policy
International Journal of Epidemiology
International Journal of Health Services
International Journal of Pharmaceutical Medicine
International Journal of Pharmacy Practice
International Journal of Quality in Health Care
Israeli Journal of Emergency Medicine
JAMA
Journal of Applied Gerontology
Journal of Emergency Medicine
Journal of General Internal Medicine
Journal of Public Policy and Marketing
Journal of Traumatic Stress
Junior Encyclopedia of Canada
Lancet
Medical Journal of Australia
Mens Sana Monographs
New York State Journal of Medicine
33
Open Medicine
Osgoode Law Journal
PharmacoEconomics
Pharmacoepidemiology and Drug Safety
Pharmacological Research
PJB Publications
PLoS Medicine
Social Science and Medicine
TIPS
Value in Health
Western Journal of Medicine
Windsor Review of Legal and Social Issues
Granting Agency Referee
Canadian Association of Emergency Physicians Research Fund
Canadian Institutes for Health Research
Father Sean O’Sullivan Research Centre
Medical Research Council
National Network on Environments and Women’s Health
Physicans’ Services Incorporated Foundation
Social Sciences and Humanities Research Council of Canada
Wellcome Foundation
Membership in Professional Organizations
Canadian Association of Emergency Physicians
Canadian Doctors for Medicare
Canadian Medical Association
College of Family Physicians of Canada
Medical Reform Group of Ontario
Ontario Medical Association
Professional Development
August 2001
1992
1984
1983
Attended Summer Institute for New Faculty Teaching at York
Diplomate, American Board of Emergency Medicine
Certificant College of Family Physicians—Emergency
Medicine
Certificant College of Family Physicians
Professional Committees
2001-2002
Member Canadian Neurosurgical Society and Canadian Spine
Society Joint Task Force on the Use of Methylprednisolone in
Acute Spinal Cord Injury
34
20011999-2000
1999
1999
1998
1995
Member World Health Organization Hypertension Guideline
Development Group
Member, Drug Quality and Therapeutics Committee, Antibiotic
Review Subcommittee for the Province of Ontario
Member, World Health Organization/Nongovernmental
Organizations Roundtable on Pharmaceutical Issues
Member, World Health Organization workshop on antibiotic
resistance
Member, Education Working Group, Ontario Round Table on
Appropriate Prescribing
Member, Canadian Medical Association Physician Prescribing
Practices Workshop Planning Committee
Interviews
Sept. 2011
Aug. 2009
Sept. 2004
Apr. 2004
Interview with Accreditation Canada about adverse drug reaction
reporting
Interview with federal Auditor General staff about drug safety in
Canada
Expert interview for EPO Scenarios project based in London, U.K.
Expert interview for Pharma Futures project based in Oxford, U.K.
TEACHING
Hospital Based
Dec. 2012
Oct. 2012
Sept. 2012
Aug. 2012
July 2012
June 2012
Jan. 2012
Dec. 2011
Nov. 2011
Sept. 2011
July 2011
June 2011
May 2011
May 2011
March 2011
Sept. 2010
March 2010
Dec. 2009
Oct. 2009
Sept. 2009
August 2009
Clinical teaching for medical students
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
Clinical teaching for PGY1 residents
Practice oral examiner for FRCP residents
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
Journal club, Emergency Department, University Health Network
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
Practice oral examiner for FRCP residents
One-on-one teaching for FRCP resident
Journal club, Emergency Department, University Health Network
Clinical teaching for PGY1 residents
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
Clinical teaching for residents in UHN emergency department
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
35
July 2009
March 2009
January 2006
One-on-one teaching for FRCP resident
One-on-one teaching for FRCP resident
Session for family medicine residents at University Health
Network on the relationship between doctors and the
pharmaceutical industry
Sept. 2005
Interactions between doctors and drug companies, grand rounds
for medical students and interns in emergency department,
University Health Network
June 2005
What do we know about antidepressants? Clinical Epidemiology
Rounds, St. Michael’s Hospital,
April 2004
Diverticulitis General surgery and emergency medicine combined
rounds, University Health Network,
Aug 2003
Medical clearance for FRCP residents in psychiatry, University
Health Network
Oct. 2008, June 2007, March 2007, Jan. 2007, Sept. 2006, April 2006, Oct 2002, Aug
2001, May 2001, Apr 2001, June 1999, Sept 1998, Sept 1997, Apr
1997, Feb 1996, June 1995, May 1995, Jan 1995, Nov 1994, Sept
1994, Aug 1994, June 1994, Oct 1992,
Seminar for clinical clerks, interns and residents,
University
Health Network (Toronto) and Lyell
McEwin Health Service
(Adelaide, Australia)
June 1996
Design and lead one day seminar for Addiction Research
Foundation Summer Institute Course. Title: Pills & Prescribing—
For Better or For Worse
Feb. 1996, Feb. 1995, June 1993, Apr 1992, Dec 1991
Lectures for paramedic students, Toronto General Hospital
January 1994
Seminar for CCFP(EM) and first year FRCP emergency
residents
Sept-Nov 1993
Clinical instructor third year comprehensive clinics
August 1993
Seminar for CCFP(EM) and first year FRCP emergency
residents, University of Toronto
August 1993
Inservice on drug overdoses for emergency nurses, Toronto
Western hospital
Nov. 1992Clinical instructor third year comprehensive clinics
Apr 1993
Nov. 1992
Epidemiology seminars for Dr. D. Baggs as part of administrative
elective in emergency medicine residency, University of Toronto
Oct. 1992
Seminar for CCFP(EM) and first year FRCP emergency
residents, University of Toronto
Aug. 1992
Epidemiology seminars for Dr. D. Cass as part of administrative
elective in emergency medicine residency, University of Toronto
June 1992
Epidemiology seminars for Dr. J. McNabb as part of
administrative elective in emergency medicine residency,
University of Toronto
Oct-Dec 1991
Clinical instructor third year comprehensive clinics
Sept. 1991
Presentation at postgraduate emergency rounds
36
May 1991
Jan 1991
Presentation at postgraduate emergency rounds
Didactic teaching session on therapeutics to emergency
medicine residents, McMaster University
University of Toronto
May 2012
Nov. 2011
May 2011
May 2010
May 2010
March 2009
Sept. 2008
May 2007
April 2007
March 2007
March 2007
May 2006
May 2006
Ethics seminar for FRCP residents
Clinical epidemiology seminar for FRCP residents
Ethics seminar for FRCP residents
Clinical epidemiology seminar for FRCP residents
Ethics seminar for FRCP residents
Practice oral examinations for FRCP residents
Guest epidemiologist for journal club for FRCP residents
Clinical epidemiology for FRCP residents
Guest lecturer in University College Health Studies Program
City-wide grand rounds
Endocrinology seminar for FRCP residents
Clinical epidemiology for FRCP residents
Panelist for session on relationships with the pharmaceutical
industry at Ethics Seminar for residents
May 2005
Clinical epidemiology for FRCP residents
March 2005
Endocrinology seminar for FRCP residents
Feb. – April 2005
Mentor, Career Explorations in Medicine
January 2005
City-wide morbidity and mortality rounds,
May 2004
Clinical epidemiology for FRCP residents
March 2004
Endocrinology seminar for FRCP residents
Oct. 2003
Health Promotion Summer School Accreditation Committee
Mar. 2003
Clinical epidemiology for FRCP residents
September 2002
Post graduate emergency medicine rounds
June 2002
Post graduate emergency medicine rounds
March 2006, Apr 2005, Nov 2003, Nov 2002, Apr 2002, Jan 2002, July 2001, Oct 2000,
Sept 1998, Oct 1997, Mar 1997, Nov 1996
University of Toronto Core cardiology, toxicology and trauma
seminars for all clinical clerks doing emergency medicine
rotation
Sept 2001, Nov 1998, Mar 1998, Oct 1997, Apr 1997, Sept 1997
Guest epidemiologist, FRCP residents journal club
Sept. 1997
Examiner, practice oral examinations for FRCP residents
Apr. 1995
Marker for practice written examination for FRCP residents
Apr 1994
Lecture to third year medical students as part of clinical
pharmacology course
Jan 1994
Lecture to second year pharmacy students
Sept. 1993
Presentation at postgraduate emergency rounds
Feb 1993
Lecture to third year medical students as part of clinical
pharmacology course
Jan. 1993
Seminar for senior FRCP emergency residents
37
Jan 1993
Oct 1992
Mar 1992
Feb 1992
Mar 1991
Feb 1991
Mar 1990
Lecture to second year pharmacy students
Lecture to second year pharmacy students
Lecture to second year pharmacy students
Lecture to third year medical students as part of clinical
pharmacology course
Lecture to second year pharmacy students
Lecture to third year medical students as part of clinical
pharmacology course
Lecture to third year medical students as part of clinical
pharmacology course
UNDERGRADUATE
York University - Course director & tutorial leader
Jan 2012-Mar 2012
Sept 2011-Dec 2011
Sept 2010-Dec 2010
Jan 2010-Apr 2010
Sept 2009-Dec 2009
Sept 2009-Dec 2009
Feb 2009-May 2009
Feb 2009-May 2009
Sept 2008-Feb 2009
Sept 2008-Feb 2009
Jan 2007-Apr 2007
Sept 2006-Dec 2006
Sept 2006-Dec. 2006
January 2006April 2006
January 2006-April 2006
Sept 2005-Dec. 2005
May 2005-June 2005
Course director HLST 3015 3.0: Pharmaceutical Policy
Course director HLST 3120 3.0 Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 3120 3.0 Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 3015 3.0: Pharmaceutical Policy
Course director HLST 3120 3.0: Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 3110 3.0: Major Themes in Health
Policy in Canada
Course director HLST 3540 3.0: International Agencies in
Health Care
Course director HLST 1011 3.0: Foundations of Health
Studies
Course director HLST 3120 3.0: Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 3110 3.0: Major Themes in Health
Policy in Canada
Course director HLST 1011 3.0: Foundations of Health
Studies
Course director HLST 3540 3.0: International Agencies in
Health Care
Course director HLST 3110 3.0: Major Themes in Health
Policy in Canada
Course director HLST 3120 3.0: Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 1011 3.0; Foundations of Health
Studies
Course director HLST 3110 3.0: Major Themes in Health
Policy in Canada
Course director HLST 3015 3.0: Pharmaceutical Policy
38
Jan.2005-April 2005
Sept 2005-Dec. 2005
May 2005-June 2005
January 2005April 2005
January 2005-April 2005
May 2004-June 2004
January 2004April 2004
January 2004April 2004
September 2003December 2003
September 2003December 2003
September 2003April 2004
January 2003April 2003
January 2003April 2003
September 2002December 2002
September 2002April 2003
May-June 2002
May-June 2002
September 2001April 2002
Course director HLST 3120 3.0: Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 3110 3.0: Major Themes in Health
Policy in Canada
Course director HLST 3015 3.0: Pharmaceutical Policy
Course director HLST 3120 3.0: Health Policy II:
Analyzing Process of Power and Politics
Course director HLST 1011 3.0; Foundations of Health
Studies
Course director HLST 3540 3.0: International Agencies in
Health Care
Course director HLST 3015 3.0: Pharmaceutical Policy
Co-course director and co-instructor in HLST 3120 3.0:
Health Policy II: Analyzing Process of Power and Politics
Co-course director and co-instructor in HLST 2020 3.0:
Health Policy: Power and Politics
Course director HLST 3110 3.0: History of Health Policy
in Canada
Co-course director and tutorial leader HLST 1000 6.0:
Introduction to Health Studies
Course director HLST 3015 3.0: Pharmaceutical Policy
Co-course director and co-instructor in HLST 3120 3.0:
Health Policy II: Analyzing Process of Power and Politics
Co-course director and co-instructor in HLST 2020 3.0:
Health Policy: Power and Politics
Tutorial leader and 5 lectures in AK/HLST 6.0 1000:
Introduction to Health Studies
Co-course director and 5 lectures in AK/HLST 6.0 1000:
Introduction to Health Studies
Co-course director and co-instructor in HLST 2020 3.0:
Health Policy: Power and Politics
Co-course director, tutorial leader and 5 lectures in
AK/HLST 6.0 1000: Introduction to Health Studies
Course development (alone)
HLST 1011 3.0: Foundations of Health Studies
HLST 3015 3.0: Pharmaceutical Policy
HLST 3110 3.0: Major Themes in Health Policy in Canada
HLST 3120 3.0: Health Policy II: Analyzing Process of Power and Politics
HLST 3540 3.0: International Agencies in Health Care
Course development (in collaboration)
39
HLST 6.0 1000: Introduction to Health Studies
HLST 2020 3.0: Health Policy: Power and Politics
York University – Guest Lectures
March 2011
January-February 2002
Feb 1998
Oct 1995
Jan 1995
Mar 1994
Feb 1994
Jan 1992
Jan 1992
Dec 1991
Mar 1991
Feb 1991
Jan 1991
Mar 1990
Mar 1988
Nov 1987
Nov 1987
Oct 1985
Drugs and the emergency department HLST 1011
2 guest lectures in Professional Ethics in Health Care `
(AK/PHIL 3000W)
Lecture to sociology students
Lecture to sociology students
Lecture to political science students
Lecture to sociology students, Glendon College
Lecture to sociology students
Lecture to sociology students
Lecture to sociology students
Lecture to sociology students, Glendon College
Lecture to sociology students, Glendon College
Lecture to sociology students
Lecture to sociology students
Lecture to sociology students
Health and Society: Critical Perspectives
Lecture to political science students
Lecture to sociology students
Lecture to sociology students
GRADUATE
York University – Course director
Jan. – Mar. 2012
Jan. – Apr. 2011
Jan. – Apr. 2010
HLTH 5030 Health and Politics
HLTH 5440 Globalization, Pharmaceuticals and Equity
HLTH 5030 Health and Politics
Course development (alone)
HLTH 5030: Health and Politics
HLTH 5440: Globalization, Pharmaceuticals and Equity
York University – Guest Lectures
Jan. 2012
May 2011
April 2011
Disease mongering CDIS 6140 Health and Disability
Drug safety and effectiveness monitoring GS Law 6859:
Pharmaceutical regulation
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry? GS Law 6867P: Human Rights,
Globalization and Health Law
40
March 2011
Mar. 2010
Nov. 2009
April 2007
Feb. 2005
Mar. 2001
Lecture for Health and Illness (Sociology 6831 3.0)
Disease mongering CDIS 6140 Health and Disability
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry? Nursing 4100 Health and Healing:
Global Context of Nursing
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry? GS Law 6867P Human Rights,
Globalization and Health Law
Globalization and the pharmaceutical industry GS Law 6867P
Human Rights, Globalization and Health Law
Seminar, Colloquium Committee Department of Sociology,
York University
University of Toronto – Guest Lectures
Nov. 2012
Nov. 2011
Oct. 2011
Oct. 2011
April 2011
April 2010
Feb. 2010
Nov. 2009
Nov. 2006
April 2006
Nov. 2005
Mar. 2004
Mar. 2003
Feb. 2002
Nov. 1998
Nov 1994
Dec 1990
Lecture for Health and Pharmaceuticals course in Health Studies
program
Lecture for Health and Pharmaceuticals course in Health Studies
program
Lecture on the Canadian drug safety system for Law3871H1F:
Governance of Pharmaceuticals in the International Context
Lecture on primary care for Pharmacy 227F Health Systems in
Society
Lecture on Evergreening for Law701H1S: Governance of
Pharmaceuticals in the International Context
Panel on pharmaceutical issues for HAD 5020: Canada’s Health
System and Health Policy II
Lecture for Health and Pharmaceuticals course in Health Studies
program
Lecture on Pharmacare for HAD 5020: Canada’s Health System
and Health Policy I
Lecture for second year students in Masters of Information Science
program
Seminar for University of Toronto law class on catastrophic drug
insurance
Lecture for second year students in Masters of Information Science
program
Seminar for University of Toronto law class on U.S. Medicare
drug benefit
Seminar for University of Toronto law class on pharmacare,
Seminar for University of Toronto law class on pharmaceutical
industry
Graduate seminar, OISE
Graduate seminar, Faculty of Pharmacy
Graduate seminar, Faculty of Pharmacy
41
Other Universities – Guest Lectures
Nov. 2010
Feb. 2009
May 2008
May 2008
Mar. 2008
Nov. 2007
Oct. 2007
Mar. 2007
Feb. 2007
Mar. 2006
Feb. 2006
Mar. 2005
Feb. 2005
Mar. 2004
Feb. 2004
Mar. 2003
Mar. 2001
Feb. 2000
Mar 1993
July 1991
Jan 1991
HSCI 305, The Canadian Health Care System, Simon Fraser
University, Vancouver
Lecture on Canadian drug regulatory system for 2nd year pharmacy
students, University of Waterloo, Waterloo ON.
The Canadian health care system: a brief introduction lecture to
first year students in Bachelor of Health Sciences programme at
Flinders University, Adelaide, Australia
Doctors, gifts and drug companies lecture to second year medical
students, Flinders University, Adelaide, Australia
Lecture on pharmaceutical industry to students in public health in
New Zealand (by telephone)
Canadian health care system: an introduction. Masters’ students in
health administration, University College Cork.
Lecture on pharmaceutical industry and developing countries to
third year students in public health program, University College
Cork.
Lecture on pharmaceutical industry to students in public health in
New Zealand (by telephone)
The pharmaceutical industry and its priorities: profits versus health
Talk for 2nd and 3rd year health law course, University of Ottawa
Lecture on pharmaceutical industry to students in public health in
New Zealand (by telephone)
The pharmaceutical industry and its priorities: profits versus health
Talk for 2nd and 3rd year health law course, University of Ottawa
Lecture on pharmaceutical industry to students in public health in
New Zealand (by telephone)
The pharmaceutical industry and its priorities: profits versus health
Talk for 2nd and 3rd year health law course, University of Ottawa
Lecture on pharmaceutical industry to students in public health in
New Zealand (by telephone)
The pharmaceutical industry and its priorities: profits versus health
Talk for 2nd and 3rd year health law course, University of Ottawa
Lecture on pharmaceutical industry to students in public health in
New Zealand (by telephone)
Audioconference lecture to class at Otago University, Health
Services Organisation and Management, New Zealand
Lecture as part of Drugs and Society course, University of South
Australia
Unit 5 Large Group Session Speaker, McMaster University,
Hamilton
Seminar for Family Practice Residents, Dalhousie University,
Halifax
Lecture to sociology students, Ryerson Polytechnic University,
Toronto
42
June 1988
Oct 1988
Mar 1987
Nov 1986
Mar 1986
Oct 1985
Family Practice Residents, Dalhousie University, Halifax
Family Practice Preceptors, University of Western Ontario,
London
Centre for Social Concern, King's College, London
Lecture to first year medical students, McMaster University,
Hamilton
Community medicine rounds, School of Medicine,
University of Auckland
Seminar for family practice residents, McMaster University,
Hamilton
Supervisor
2011 – 2012
2011 – 2012
2010 – 2011
2010 - 2011
2010 - 2010
2009 - 2010
2009 - 2010
2009 – 2010
Natasha Pasher, MA Graduate Program in Health, York University
Title: The exclusion of home care services from the provisions of
the Canada Health Act: equity implications from a gendered lens
Completion: Summer 2012
Adrienne Schnier, MA Graduate Program in Health, York
University
Title: Authorship polices and ghostwriting in medical journals: a
political economy perspective
Completion: Summer 2012
Barbara Piljic, MA Graduate Program in Health, York University
Title: Canada’s drug regulatory system: women’s use of selective
serotonin reuptake inhibitors
Completion: Summer 2011
Lisa Norton, MA Communications and Culture, York University
Title: Direct-to-Consumer Advertising (DTCA) of prescription
drugs on the internet: a comparison of Canadian and American
drug websites in the context of DTCA policy
Completion: Summer 2011
Kathleen Malisani, MA Critical Disability Studies, York
University
Title: Pre-implantation genetic modification of embryos and
disability theory: obligation or discrimination
Completion: Summer 2010
Clement Ampong, MA Public Policy, York University
Title: The impact of the Toronto Central Local Health Integrated
Network (TCLHIN) wait time strategy on two hospitals in
reducing hip and knee surgical replacement wait times.
Completion: Summer 2010
Turgay Kirbiyik, MA Public Policy, York University
Title: Drug safety regulatory systems in Canada and the U.S.
Whose interests are being met?
Completion: Summer 2010
Liane Daiter, BA Health and Society, York University
43
Title: An exploration of breast cancer treatment, diagnosis and
prevention coverage in Canadian newspapers
Completion: Spring 2010
Supervisory committee membership
2010 – 2011
2010 2010
2010
2009 2008 - 2009
2006-2007
2006-2008
2006-2007
2005-2009
2005-2010
2004-2010
Glenyx Pei, MA Graduate Program in Health, York University
Title: Prospects and pitfalls of phased retirement in Ontario
universities
Completion: Summer 2011
Al Barone, PhD Philosophy, York University
Syeda Kabir, MA Graduate Program in Health, York University
Title: A critical political economy perspective to policies and
practices involving type 2 diabetes prevalence in Canada
Completion: Fall 2010
Jaineel Purohit, MA Graduate Program in Health, York University
Title: Do the LHINs have the ability to raise awareness of the
social determinants of health and reduce health inequities?
Completion: Fall 2010
Marietta Jasper, MA Critical Disability Studies, York University
Robinder Bahniwal, MA Critical Disability Studies, York
University
Title: c
Completion September 2009
Iphigenia Mikroyiannakis, MA Critical Disability Studies, York
University
Title: A physician’s influence on the life of a person with a
disability
Completion: Fall 2007
Jason Steele, MA Critical Disabilty Studies, York University (not
completed)
Jackie Choiniere, PhD in Sociology, York University
Title: Accounting for care: the costs of managerial
transformations in nurses’ practices
Completion: Fall 2007
Marc-André Gagnon, PhD in Political Science, York University
Title: The nature of capital in the knowledge based economy: the
case of the global pharmaceutical industry
Completion: Spring 2009
Albert Banerjee, PhD in sociology, York University
Title: On the frontlines: structural violence in Canadian long-term
residential care
Completion: Fall 2010
Laura Esmail, PhD in pharmacy, University of Toronto (advisory
capacity)
44
20042003-2007
2003-2006
1999-2003
Title: The politics of Canada’s access to medicines regime: the
dogs that didn’t bark
Completion: Summer 2010
E. Suzanne Peters, PhD in sociology, York University
(Withdrawn)
Deborah Davidson, PhD in women’s studies, York University
Title: The Emergence of Hospital Protocols for Perinatal Loss,
1950-2000.
Completion: Fall 2007
Eshrak Zaki, PhD in sociology, University of Toronto
Title: The impact of global and local factors on drug accessibility
in Egypt
Completion: Summer 2006
Barbara Mintzes, PhD in clinical epidemiology, University of
British Columbia
Title: An assessment of the health system impacts of direct-toconsumer advertising of prescription drugs (DTCA)
Completion: Spring 2003
PhD comprehensive committees
2012
Julie Brassolotto.
External thesis examiner/reader/outside examiner
2012
2012
2010
2009
2009
2009
2007-2008
2006
2005
Marie-Clare Hogue, PhD, University of Newcastle, Pharmaceutical
promotion and consumers: unpacking the assumptions. Completed 2012
Aria Ilyad Ahmad, MSc, University of Toronto, Addressing variability in
drug quality: finding the right “quality” framework(s). Completed 2012
Noordin Othman, PhD, University of South Australia, Quality of
information in pharmaceutical promotion. Completed 2010
Andrew Searles, PhD, University of Newcastle, A preliminary analysis of
the pharmaceutical provisions in the Australia-United States Free Trade
Agreement on prescription medicines in Australia. Completed 2009
Chantelle Garritty, MA, University of Toronto, Updating Systematic
Reviews: the Policies and Practices of Health Care Organizations
Involved in Evidence Synthesis. Completed 2009
Antonia Swan, PhD, York University Essays in competition, innovation,
R&D and pricing. Completed 2009
Janine Arkinson, MSc, McMaster University Public opinion of
physician-pharmaceutical industry interactions. Completed 2008
Dafna Knittel-Keren, MA, York University Women’s narratives of recovery from depression: the personal experiences vs. the clinical
perspectives. Completed 2006
Maureen Helt, LLM, York University Access to medicines and the right to
health. Completed 2005
45
2004
2003
2002
1998
1995
Suzanne Share, MA, York University
The inclusion of people with disabilities as an identifiable group in the
Hate Propaganda Section 318 of the Criminal Code of Canada. Complete:
2004
Nicole Brazier, MSc, McMaster University
Title: The association between physicians’ values and the relative
importance of self-attribution: a pilot study. Completed: 2003
Dr. Anna Stevenson, MPH, University of Otago, New Zealand
Title: Direct to consumer advertising (DTCA) of prescription medicines: a
preliminary analysis. Completed 2002
Libby Roughead, PhD, University of South Australia, Adelaide, Australia
Title: Approaches to evaluating Australia's quality use of medications
policy. Completed: 1998
Libby Roughead, MSc, LaTrobe University, Melbourne, Australia
Title: The Pharmaceutical Representative and Medical Practitioner
Encounter: Implications for Quality Use of Medicines. Completed: 1995
OTHER TEACHING RELATED ACTIVITIES
Teaching Awards Nominated/Received
2006
1998
1997
Nominated for Dean’s Teaching Award, Atkinson Faculty
Winner, Anna Jarvis Teaching Award, FRCP Emergency Medicine
program, University of Toronto
Nominated for the Anna Jarvis Teaching Award in the FRCP Emergency
Medicine program, University of Toronto
Professional Societies
1996
1995
1992
1991
Examiner for CCFP(EM) exam
Examiner for CCFP(EM) exam
Examiner for CCFP(EM) exam
Examiner for CCFP(EM) exam
Course Development
2011
2009
2004
2003
2002
2002
2002
GS/HLTH 5440 3.0: Globalization, Pharmaceuticals and Equity
GS/HLTH 5030 3.0: Health and Politics
AK/HLST 3540 3.0: International Agencies in Health Care
AK/HLST 3110 3.0: History of Health Policy in Canada
AK/HLST 3015 3.0: Pharmaceutical Policy and Politics
AK/HLST 3120 3.0: Health Policy II: Analyzing Processes of Power and
Politics (with Mary Wiktorowicz)
AK/HLST 2020 3.0: Health Policy I: Power and Politics (with Mary
Wiktorowicz)
46
2001
AK/HLST 1000 6.0: Introduction to Health Studies (with Paul Grayson,
Joe Levy, Dennis Raphael, Marcia Rioux, Mary Wiktorowicz)
SERVICE
University Health Network
2005
2001
1998-99
19921992
1991-1992
1991
1990-1992
Instructor, nurses recertification in cardiac care
Hiring committee for nurse manager, emergency department, Toronto
General Hospital
Member, executive committee to plan for emergency department
reconstruction
Member, Pharmacy and Therapeutics Committee
Chair ad-hoc committee on physician schedule revision, Emergency
Department, The Toronto Hospital
Member, Information Committee, Emergency Department, The Toronto
Hospital
Revision of sections of Policies and Procedure Manual, Emergency
Department, The Toronto Hospital
Member, manuscript evaluation committee, Emergency Department, The
Toronto Hospital
Hamilton Civic Hospitals
1987
1985-1988
1982-1988
Member of recruitment committee, Emergency Department
Hamilton Civic Hospitals
Participation in peer review program, Department of Emergency
Medicine,Hamilton Civic Hospitals
Attendance and participation at staff emergency rounds, Hamilton Civic
Hospitals. Presentation topics: diving and swimming emergencies,
empiric outpatient use of antibiotics, bicycle accidents, emergency
medicine in New Zealand, physicians’ prescribing behaviour
University of Toronto
Sept. 2004
1999
1998-99
External reviewer for promotion application in Department of Family and
Community Medicine, Faculty of Medicine
Co-organizer, annual research day, FRCP Emergency Medicine Residency
program, University of Toronto
Co-research coordinator, FRCP Emergency Medicine Research program,
University of Toronto
Government of Canada
2005
Invited participant, Drug safety and effectiveness in the real world: a
47
1999-2002
1998
working conference, Health Canada
Member, Working Group, Patented Medicine Prices Review Board,
Health Canada
Member, Audit Advisory Committee for Auditor General, Government of
Canada. Advised on conduct of audit on Patented Medicine Prices Review
Board
Government of Ontario
April 2005
Product review for Drug Quality and Therapeutics Committee
York University
Oct. 2011
Representative from SHPM at Agents for Change event organized by
SAHPMI
Representative from Faculty of Health at Ontario University Fair
Speaker from SHPM at FHSC Meet and Greet
Tenure and Promotion Committee, Faculty of Health
Graduate education task force, Faculty of Health
Hiring committee member for Health Informatics position in School of
Health Policy and Management
Oct. 2011
Oct. 2011
Sept. 2011 Sept. 2011 Jan. 2011 Mar. 2011
Sept. 2010 –
Sept. 2011
Academic Freedom Working Group, York University
Sept. 2010
Representative from Faculty of Health at Ontario University Fair
Aug. 2010 - Co-graduate program director (with Marcia Rioux), Graduate Program in
Health
Dec. 2009 – Subcommittee to investigate establishment of BA in Global Health,
Mar. 2010
Faculty of Health
Sept. 2009
Representative from Faculty of Health at Ontario University Fair
Sept. 2008
Representative from Faculty of Health at Ontario University Fair
Sept. 2009 - Executive committee, Graduate Program in Health
Sept. 2008 – Senate Tenure and Promotions Committee
June 2011
May – June Chair, Hiring Committee for CLA position in School of Health Policy and
2007
Management
Jan – Apr
2007
Guiding Coalition member, Faculty of Health
Sept. 2006 – Curriculum Committee, Faculty of Health
June 2007
July 2006 – Senate Tenure and Promotions Committee
June 2007
Nov. 2005
Panelist, The Politically Active Sociologist, Department of Sociology
Oct. 2005Chair, Hiring Committee for position in Health Management/Health
Dec. 2005
Services Research
Oct. 2005
Representative of School of Health Policy and Management at booth at
Ontario Hospital Association annual convention
48
Sept. 2005
Sept. 2005
Sept. 2005June 2006
Feb. 2005 –
June 2007
Representative from Atkinson at Ontario University Fair
Attended orientation for new Atkinson students as representative of
School of Health Policy and Management
Co-chair, Atkinson Tenure and Promotion Committee
Member of committee to develop pan-university graduate program in
Health
Feb. 2005 –
June 2007
One of leads in School of Health Policy and Management in developing
proposal for graduate program in Health Policy and Equity
January 2005- Development of proposal for Certificate in Health Studies
June 2005
Feb. 2005
Representative from School of Health Policy and Management to
committee to examine proposal for Faculty of Health
Nov. 2004- Member, Hiring Committee for joint position School of Health Policy and
April 2005
Management and Administrative Studies
Oct. 2004Member, Merit Pay Committee, Atkinson Faculty
Nov. 2004
Oct. 2004
Coordinated School of Health Policy and Management response to the
Task Force on Student Learning
Oct. 2004
Member of Adjudicating Committee on progress from Pre-Candidacy to
Candidacy for two faculty members
Sept. 2004- Member, Atkinson Tenure and Promotion Committee
June 2005
2004-2005
Developed proposal for graduate program in Health Policy and Health
Equity in School of Health Policy and Management
March 2004- Member, Hiring Committee for joint position School of Health Policy and
May 2004
Management and Administrative Studies
Jan. 2004Member, Hiring Committee for joint position School of Health Policy and
April 2004
Management and Nursing
2003-2004
Member of committee to look at developing joint LLB/MA in health
policy with Osgoode Faculty of Law
2003-2004
Responsible for preparing bylaws, T&P standards and Affirmative Action
Plan for School of Health Policy and Management
Sept. 2003
Representative from Atkinson at Ontario University Fair
Sept. 2003
Orientation for new students in School of Health Policy and Management
June 2003
Computer question and answer session for prospective Atkinson students
Sept. 2003June 2008
Associate Chair, School of Health Policy and Management
Sept. 2002
Representative from Atkinson at Ontario University Fair
2001-2002
Chair, Hiring Committee, School of Health Policy and Management
2001-2004
Member, Curriculum Committee, Atkinson Faculty of Liberal and
Professional Studies
Nov. 2002
Panelist, Globalization and research ethics in the multinational
pharmaceutical industry, Research Ethics—A Discussion
49
Sept. 2001Sept. 2001
Co-director coop program, School of Health Policy and Management
Representative from Atkinson at Ontario University Fair
International Community
Sept. 2007April 2006
April 2005
Nov. 2004
2004Sept. 2004
2003
2002, 2003
2002-2005
2001
1999-2002
1998-2004
1997-2000
1994-1997
Member, Health Action International – Europe, Association Board (based
in Amsterdam)
Meeting with two consultants from OECD regarding Pharmaceutical
Pricing Policies & Innovation Project
Reviewer for Geneva Infant Feeding Association (member organization of
International Baby Food Action Network) of paper on conflict of interest
External reviewer for tenure application for candidate at University of
Texas
Member, management group Health Skepticism (based in Adelaide,
Australia)
Expert advice on implications of trade agreements on pharmaceutical
policy to authors of How to kill a country: Australia’s devastating trade
deal with the United States
Reviewer for two drafts of WHO paper on WHO Guidelines on Safety
Monitoring and Pharmacovigilance of Herbal Medicines
Reviewer for two drafts of WHO paper on WHO Guidelines for
Consumers on Proper Use of Traditional Medicine and
Complementary/Alternative Medicine
Member, Health Action International, International Steering Group
Invited participant, WHO meeting on antibiotic resistance
Non-governmental organization representative on the WHO/NGO
Roundtable on Pharmaceuticals
Member, Health Action International – Europe Association Board
Secretary and board member, MaLAM Inc. (Medical Lobby
for Appropriate Marketing)
President and board member, MaLAM Inc. (Medical Lobby
for Appropriate Marketing)
EXTRA-UNIVERSITY COMMUNITY SERVICE
Advisory committees
Feb. 2007
Member of health policy advisory committee to help formulate
federal NDP health policy
Lectures and panels
Oct. 2012
Sept. 2012
From the emergency department to health policy: an unplanned
journey. Calumet College Speakers Series, York University
Evergreening: patents and money. Toronto Health Economics and
50
Mar. 2012
Mar. 2012
Mar. 2012
Jan. 2012
Dec. 2011
Oct. 2011
Oct. 2011
Oct. 2011
Oct. 2011
June 2011
May 2011
May 2011
May 2011
April 2011
Mar. 2011
Feb. 2011
Nov. 2010
Technology Assessment (THETA) Collaborative, Toronto
Whose conflicts, whose interests? Video lecture to seminar on
Transparency and Ties in Medicine, Finish Medical Society
Duodecim, Helsinki
Invited participant, roundtable on Enhancing Canadians’
prescription drug coverage, sponsored by Canadian Life and
Health Insurance Association (CLHIA) and the Center for Health
Economics and Policy Analysis, Hamilton
Living better through chemistry: dementia, long-term care and
antipsychotic medication use. Advanced Seminar Series, Major
Collaborative Research Initiative on Reimagining Long-Term
Care, York University
Talk for GRASP (Graduate Research Association of Students in
Public Health): Advancing research for neglected diseases
Doctors and drug companies: too close for comfort at Department
of Clinical Pharmacology, Sunnybrook Health Sciences Centre
Workshop on the Canadian health care system. Physicians for a
National Health Program annual meeting, Washington
Presentation to Expert Advisory Committee on the Vigilance of
Health Products, Health Canada, Toronto
Those who have the gold make the evidence: the pharmaceutical
industry and clinical trials for Health Law and Ethics seminar
series, Faculty of Law, University of Toronto
Lecture on doctors and drug companies for 2nd year medical
students at McMaster as part of Professional Competencies lecture
series
Panelist, Medical education at Pharma Knows Best: Managing
Medical Knowledge, Washington
Doctors, gifts and the pharmaceutical industry, talk to medical
students at McMaster University as part of Social Medicine
elective, Hamilton
Panelist, Healthcare corruption in Canada: is it a threat to public
health, Spotlight on Anti-Corruption: Current Issues, Day of
Dialogue, Transparency International Canada, Toronto
Session on pharmaceutical policy for The International Program in
Health Policy and Practice (Harkness Canadian Health Policy
Briefing Tour), The Commonwealth Fund, Toronto
Talk for GRASP (Graduate Research Association of Students in
Public Health): Drug companies in the developing world: what
should we expect?
Talk on Pharmacare to board of Ontario Society of Senior
Citizens’ Organizations, Toronto
Panelist Relationship between pharmaceutical industry and NPs,
Nurse Practitioners: Essential Partners in Improving the Health
Care System, Ontario Hospital Association, Toronto
Regulation of physicians in Canada. For visiting Chinese health
51
Nov. 2010
Nov. 2010
Nov. 2010
Nov. 2010
May 2010
May 2010
May 2010
April 2010
Jan. 2010
Jan. 2010
Sept. 2009
April 2009
March 2009
Jan. 2009
Jan. 2009
Oct. 2008
Sept. 2008
June 2008
May 2008
May 2008
officials from Chongqing, York University
Webinar, Keeping an Eye on Prescription Drugs, Keeping
Canadians Safe, Health Council of Canada, Toronto
Selling of Viagra. Cinema Politica, Toronto
Workshop on the Canadian health care system. Physicians for a
National Health Program annual meeting, Denver
Canadian drug prices: the good, the bad and the ugly. Physicians
for a National Health Program annual meeting, Denver
Closing plenary. Students for Medicare conference, Toronto
Pharmacare – Canadians have waited too long. Students for
Medicare conference, Toronto
Session on pharmaceutical policy for The International Program in
Health Policy and Practice (Harkness Canadian Health Policy
Briefing Tour), The Commonwealth Fund, Toronto
Panel discussion following film Generation Rx, MUCK (Movies
of Un-common Knowledge) film festival, Toronto
Pharmacare – Canadians have waited too long. Community Health
and Humanities Seminar Series, Memorial University of
Newfoundland, St. John’s
Relationship between doctors and drug companies. Taddlecreek
Family Health Network, Toronto
Panel discussion on H1N1 flu. Organized by Trinity Spadina NDP
Riding Association, Toronto
Pills, prices and promotion: a quick trip through some
contemporary pharmaceutical policy issues for 7th Annual Health
Innovation and Policy Summit, Toronto
Workshop on Pharmacare for Medicare: It’s Time to Act, Students
for Medicare, Toronto
Panelist on effects of hospitals cuts on patients. Ontario Health
Coalition Strategy Summit on Ontario’s Planned Hospital Cuts,
Downsizing and Restructuring, Toronto
Panelist on relationship betweeen doctors and the pharmaceutical
industry for City-wide Emergency Medicine Grand Rounds,
Toronto
The common drug review: an international comparison for Centre
for the Evaluation of Medicines, Hamilton
Presentation on Pharmacare to Board of Registered Nurses
Association of Ontario
Presentation on Bill C-51 to senior B.C. Pharmacare staff,
Victoria, B.C.
Whose conflicts, whose interests: financial conflicts of interest and
their effects Sansom Institute Visiting Research Scholar Seminar,
University of South Australia, Adelaide
Health recommendations from the 2020 summit: a biased
Canadian point of view. Public lecture at the Australian National
University College of Law, Canberra
52
May 2008
May 2008
Apr. 2008
Mar. 2008
Jan. 2008
Jan. 2008
Jan. 2008
Jan. 2008
Dec. 2007
Nov. 2007
Oct. 2007
Oct. 2007
Sept. 2007
May 2007
Apr. 2007
Feb. 2007
Dec. 2006
Nov. 2006
Nov. 2006
Nov. 2006
Journal club for Quality Use of Medicines and Pharmacy Research
Centre, University of South Australia
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry for Ethics Centre of South Australia
Presentation for faculty in Quality Use of Medicines and Pharmacy
Research Centre, University of South Australia
Presentation for faculty in Quality Use of Medicines and Pharmacy
Research Centre, University of South Australia
Seminar for infectious disease residents at McGill University on
relationship between doctors and the pharmaceutical industry
Whose evidence: profits, research and medical practice,
Presentation at Infectious Disease Rounds, McGill University
Doctors, gifts and drug companies, Presentation to McGill family
medicine residents, Montreal
Pharmacare: Canadians have waited too long, Presentation to
medical students at University of Western Ontario, London
Presentation to the University College Cork Ethics Committee on
Conflict of Interest, Cork
Medicine is a social science, and politics nothing but medicine on
a grand scale Seminar on Promoting Interdisciplinary Teaching in
Public Health, University College Cork.
Trust in pharmaceutical research? Trust in Science Workshop,
Toronto
Seminar for sociology department on drug regulation, University
College Cork, Cork Ireland
Panelist The cancer patient experience – from symptoms to
diagnosis, Cancer Care Ontario, Toronto
The case for pharmacare: equity, economic efficiency and
improved prescribing at S.O.S. Medicare 2: Looking Forward,
Regina
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry? at Department of Clinical
Pharmacology, Sunnybrook Health Sciences Centre
Canadian drug prices and expenditures: some statistical
observations and policy implications, Centre for Evaluation of
Medicines, Hamilton
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry? at Centre for Health Economics and
Policy Analysis seminar series, Hamilton
Hospitals and the pharmaceutical industry: an ethical challenge at
York Central Hospital, Governance Retreat, Thornhill
Are we living in an evidence b(i)ased world? at Queen’s National
Undergraduate Conference on Medicine, Kingston
Doctors and the pharmaceutical industry: too close for comfort? at
Queen’s National Undergraduate Conference on Medicine,
Kingston
53
Nov. 2006
Oct. 2006
June 2006
May 2006
May 2006
March 2006
March 2006
February 2006
Dec. 2005
Oct. 2005
Sept. 2005
Sept. 2005
June 2005
June 2005
April 2005
April 2005
Mar. 2005
Mar. 2005
Feb. 2005
How Canada controls drug costs at Physicians for a National
Health Program annual meeting, Boston
MP Breakfast talk on Pharmacare for Canadian Federation of
Nurses Unions, Ottawa
Panelist, What’s working: privacy and security approaches in
today’s healthcare environment at Identity Theft and Information
Security in Healthcare, Toronto
Session on pharmaceutical policy for The International Program in
Health Policy and Practice (Harkness Canadian Health Policy
Briefing Tour), The Commonwealth Fund, Toronto
Doctors and drug companies: too close for comfort at Radical
Caucus of the American Psychiatric Association, Toronto
What do doctors know about antidepressants and who tells us? at
Canadian premier of Prescription: Suicide, Toronto
Canada and compulsory licensing: private profits versus public
health at Killing Innovation or Saving Lives: Competing Visions
for Compulsory Licensing in Canada. Technology & Intellectual
Property Group, Faculty of Law, University of Toronto.
Who will adopt the orphans: drugs, approvals, CDR and provinces
at Comprehensive Care for Rare Blood Disorders, Toronto
How Canada controls drug costs at Physicians for a National
Health Program annual meeting, Philadelphia
Hospital drug costs: problems and solutions at Conference on
Hospital Reform, Ontario Health Coalition, Toronto
Canadian drug regulation: time for a new paradigm? Lecture for
health management students from University College Cork
(Ireland), York University
Threats to medicare and other bogeymen. Talk for Canadian
AutoWorkers Retirees, Port Elgin
Invited participant, Workshop on Registration and Disclosure of
Clinical Trials, Health Canada, Ottawa
Minimizing the economic impact when adverse drug events occur
at Drug Safety Summit 2005: a Pharmaceutical Forum, Canadian
Institute, Toronto
Ethics, drugs and the developing world: what should we expect of
the pharmaceutical industry for School of Continuing Education,
University of Toronto
The overall impact of new drugs debate for Montreal Economic
Institute, Montreal
Drug safety in Canada: a personal odyssey and some analysis for
Centre for Evaluation of Medicines, Hamilton
Panelist, Pharmacare or catastrophic drug coverage, Canadian
Diabetes Leadership Forum, Ottawa
Presentation to the Board of Directors of Canadian Healthcare
Association Cost containment and appropriate utilization of
pharmaceuticals, Ottawa
54
Jan. 2005
Dec. 2004
Nov. 2004
Nov. 2004
Oct. 2004
Sept. 2004
May 2004
May 2004
May 2004
May 2004
May 2004
April 2004
April 2004
Feb. 2004
Feb. 2004
Jan. 2004
Jan. 2004
Presentation on Pharmacare to Board of Directors of
Communications, Energy and Paperworkers Union, Ottawa
Implications of industry funding of clinical research for Healthy
Skepticism, Adelaide
Panelist Are cross border drug sales putting Canadian
pharmaceutical manufacturers and Canadians at risk? Pharmac
2004, Toronto
Pharmacare and appropriate prescribing for Medical Reform
Group, Toronto
Drug safety in Canada: a personal odyssey and some lessons
learned York Institute for Health Research
Presentation to Swedish parliamentarians on Canadian drug
regulatory system, Stockholm
Doctors and the drug industry: too close for comfort? for semiannual meeting of the West Hudson Psychiatric Society, Rockton
County, New York
Public-private partnerships: a bad idea for Ontario Health
Coalition campaign The Deficit Double Cross: Private P3
Hospitals and the Downsizing of Public Health Care, Oakville
Doctors and the drug companies: too close for comfort? at
Osgoode Hall Law School/Faculty of Medicine, University of
Toronto Professional Development Program. Current Legal and
Ethical Issues for Health Care Providers: How to Steer Through
the Minefield, Toronto
Pharmaceutical trials and conflict-of-interest at Thinking Globally,
Acting Locally: Ethical Issues in International & Cross-Cultural
Research, Centre for Addiction and Mental Health, Toronto
Public-private partnerships: a bad idea for Ontario Health
Coalition campaign The Deficit Double Cross: Private P3
Hospitals and the Downsizing of Public Health Care, Oshawa
Drug prices in Canada and the United States at Tackling CrossBorder Drug Sales. Toronto
What me conflicted? Pharmaceutical industry funding of clinical
research. Rounds at Institute for Clinical and Evaluative Sciences,
Toronto
Science and drug regulation: an oxymoron? Research and the Law:
A Working Conference on Scientific Research in the Courtroom.
National Judicial Institute, Toronto
What me conflicted? Doctors and the pharmaceutical industry
Canadian Society of Hospital Pharmacists, 35th Annual
Professional Practice Conference, Toronto
Physicians and the pharmaceutical industry, talk to medical
students at McMaster University as part of Social Medicine
elective, Hamilton
Speaker, Safety last? A national roundtable on Health Canada’s
proposed changes to health protection legislation. Ottawa
55
Dec. 2003
Nov. 2003
Nov. 2003
Nov. 2003
Oct. 2003
Sept. 2003
May 2003
Feb. 2003
Feb. 2003
Feb. 2003
November 2002
September 2002
June 2002
June 2002
June 2002
May 2002
April 2002
April 2002
March 2002
Seminar for Family Practice Residents, St. Michael’s Hospital,
Toronto
Speaker, Safe Medicines & Informed Choices: Building a National
Citizens’ Network, Vancouver
Presentation at Policy Rounds, Ministry of Health, Victoria,
British Columbia
Presentation of rounds at Centre for Evaluation of Medicines,
Hamilton: What Me Conflicted: Pharmaceutical Funding of
Clinical Research?
Speaker, Globalization: Health and the Effects of Care, York
University
Panelist, Food, flattery and friendship: issues arising from clinical
trials with industry. Satellite Session to Anemia Institute National
Patient Conference, Toronto
Speaker, session on Physician/Industry Relations, McMaster
Family Practice Residents, Hamilton
Panelist, Education or marketing? The role of the pharmaceutical
industry in our professional development. A seminar organized by
University of Manitoba medical students
Physicians and the pharmaceutical industry, talk to medical
students at McMaster University as part of Social Medicine
elective, Hamilton
Panelist, Prescription for change: securing the future of public
health care. Council of Canadians, Ottawa.
Panelist, Direct-to-consumer advertising: is it really worth it?
Pharmac Sales & Marketing Summit, Toronto
Panelist, University of Toronto Department of Psychiatry Faculty
Development Series, An approach to ethical interactions with the
pharmaceutical industry Toronto
Should doctors prescribe new drugs? Rounds at Institute for
Clinical Evaluative Sciences, Toronto
Panelist, AgeQuake: Canada's Boomers Remake the
Nation,York University, Toronto
Concurrent session presenter, Determining the integrity of
breastfeeding research, 12th Annual National Breastfeeding
Seminar, Toronto
Invited participant, Driving change: infostructure: a tool for
a pan-Canadian health care system Munk Centre, Toronto
Physicians and the pharmaceutical industry, talk to medical
students at McMaster University as part of Social Medicine
elective, Hamilton
Panelist, Does public medicare work? Ontario Health Coalition,
Toronto
Physicians and the pharmaceutical industry: too close for
comfort? Post graduate emergency medicine rounds, University of
Toronto
56
February 2002
Nov. 2001
Oct. 2001
Feb. 2001
Feb. 2001
Jan. 2001
Jan. 2001
Nov. 2000
Apr. 2000
Apr. 2000
Mar. 1999
May 1998
Dec. 1997
Nov. 1997
Nov. 1997
Oct. 1997
Oct. 1997
Oct 1997
June 1997
May 1997
How good is the evidence for new drugs? Rounds at Centre for
Evaluation of Medicines, Hamilton
Free trade and prescription drugs. For the Canadian Centre
for Policy Alternatives, Vancouver
Invited commentator, Roundtable for the Romanow Commission
Globalization and its impact on the Canadian public health system,
Université Laval
Practising emergency medicine upside down: Emergency
medicine in Australia Post graduate emergency medicine rounds,
University of Toronto
Panelist, Choosing Drug Therapy: Induction, Seduction,
Deduction, Community Speakers Series, University of Toronto
Medical grand rounds, Royal Victoria Hospital, Montreal
Medical grand rounds, Montreal General Hospital, Montrea
Presentation of rounds at Centre for Evaluation of Medicines, St.
Joseph’s Hospital, Hamilton: Can Canada Afford a National
Pharmacare Plan?
Faculty seminar, Faculty of Pharmacy, University of South
Australia, Adelaide, Australia
Faculty seminar, Department of Clinical Epidemiology, Monash
University, Melbourne, Australia
Speaker, Secrecy in the Health Protection Branch Approval
Process, in Seminar Series: Public, Private, Corporate:
Challenges in Health Protection and Health Research, Centre for
Health Studies and Health and Society Program, York University
Panelist, Exploring the Relationship between Psychiatry and the
Pharmaceutical Industry at McGill Psychiatry Residents
Association Career Day, Montreal
Guest speaker, AIDS Action Now Annual General Meeting,
Toronto
The Patented Medicine Prices Review Board: A Discussion
Paper—Response at Second National Conference on
Cost-Effective Drug Therapy, Toronto
Panelist, Direct to Consumer Advertising at Second National
Conference on Cost-Effective Drug Therapy, Toronto
Panelist, Direct to Consumer Advertising in Canada: What’s
at Stake for the Industry and Consumers? C-PIC’97 (Canada’s
Pharmaceutical Industry Conference), Toronto
Invited participant, Therapeutic Products Programme workshop on
Product Licensing Framework, Ottawa
Rounds, Division of Clinical Epidemiology and Institute for
Clinical Evaluative Sciences, Toronto
Speaker at Concurrent Session Interactions Between Industry,
Physicians and Government at Seventh Annual National
Breastfeeding Seminar, Toronto
Panelist, Ethical Issues in Women’s Health: The Delicate
57
May 1997
Apr 1997
Mar. 1997
Dec. 1996
Oct 1996
May 1996
Dec 1995
Nov 1995
Oct 1995
Oct 1995
Apr 1995
Mar 1995
Oct 1994
July 1994
June 1994
Nov 1993
Nov 1993
June 1993
June 1993
Feb 1993
Feb 1993
Oct 1992
Sept. 1992
Business of Funding from Drug Companies. Sponsored by the
National Network on Environments and Women’s Health at York
University, Toronto
Noontime lecture, Dalhousie School of Pharmacy, Halifax
Rounds, Centre for Evaluation of Medicines, Hamilton
Panelist, The Relationship Between the Medical Resident and the
Pharmaceutical Industry. 6th annual Canadian Association of
Chief Medical Residents Conference, Toronto
Panelist, Tobacco and Drug Regulation: Smoke and Mirrors at
Law for the Public Interest Conference, Toronto
Lecture to family practice residents, St. Michael’s Hospital,
Toronto
Panelist, Pharmaceuticals: A Study in Cost Shifting. Centre for
Health Economics and Policy Analysis Conference, Toronto
Senior executives, Pharmacia, Mississauga.
Somecuts never heal! A public forum on Medicare. CAW Local
112. Toronto
Elderly and drug misuse. ARF Teleconference—The pain of pains:
complexities of assessment,family; suicide; elderly.
How others perceive us—listening to our critics. Medical
perspective. 1995 PMAC Medical R&D Annual (Fall) Meeting,
Toronto
Antibiotics: review of past and future use and focus on rationale
for choices, Nurse Practitioner Association of Ontario, Spring
Workshop, Toronto
Retired Men’s Club, All Souls Anglican Church. Toronto
Debate for family practice residents, Wellesley Hospital, Toronto
Presentation to British Columbia Therapeutics Initiative
Scientific Information and Education Committee, Vancouver
Talk to Medical/R&D department, Ciba-Geigy
Misuse of alcohol and other drugs by the older person: community
based prevent and intervention. COPA and ARF, Toronto
Retired Men’s Club, All Souls Anglican Church. Toronto
Drug Patent Laws: Are We Getting Our Money’s Worth?
Canadian Science Writers Association. Toronto
Marketing group, Eli Lilly. Toronto
Pills, Pills, Pills. St. Lawrence Centre for the Arts Forum.
Cosponsored by Canadian Pensioners Concerned, Toronto
Clinical pharmacology rounds, Sunnybrook Health Sciences
Centre, Toronto
Association of Jewish Seniors Annual Conference: Is Our Drug
System Unravelling: Narrowing the Information Gap, Toronto
Factors associated with lengths of stay in the emergency
department for patients. Presentation at Emergency
Medicine Research Forum, McMaster University
58
Apr 1992
Mar 1992
Sept 1989
Sept 1989
May 1989
Feb 1989
June 1988
May 1987
Mar 1987
Jan 1987
Nov 1986
Sept 1986
Sept 1986
Nov 1984
Open Forum: Promoting Health or Pushing Drugs? Geneva,
Switzerland
Talk to medical staff, Whitby Psychiatric Hospital
Hospital Pharmacy Institute: Competitive Strategies
for the Future, Ontario Hospital Association, Toronto
Concerned Friends of Ontario Citizens in Care Facilities, Toronto
Task Force on the Use and Provision of Medical Services, Toronto
(Scott Task Force)
Pharmaceutical Advertising Advisory Board, Toronto
Talk to board of Epilepsy Foundation, Toronto
Presentation on utilization of the emergency department at
conference organized by Ontario Public Service Employees Union,
Toronto.
Meeting on Bill C-22, Parkdale Community Health Centre,
Toronto
Public Meeting on Bill C-22, Toronto
Public Meeting on Bill C-22, Ottawa
UAW Retirees, Oakville
Council of the Canadian Auto Workers, Port Elgin
Ontario Public Interest Research Group, Peterborough
Media Interviews
CBC Radio
CBC Television
CTV Television
Edmonton Journal
Globe and Mail
Toronto Star
Montreal Gazette
Ottawa Citizen
National Post
Canadian Press
National Public Radio (US)
Finnish television
Swedish television
Irish Times
British Broadcasting Corporation
Various private radio stations
Various private television programs
DATE OF PREPARATION
Sept. 28, 2012
59